The Role of Nutrient Availability in Therapeutic Response of Leukemia by Guarecuco, Rohiverth, Jr
Rockefeller University 
Digital Commons @ RU 
Student Theses and Dissertations 
2021 
The Role of Nutrient Availability in Therapeutic Response of 
Leukemia 
Rohiverth Guarecuco Jr 
Follow this and additional works at: https://digitalcommons.rockefeller.edu/
student_theses_and_dissertations 














A Thesis Presented to the Faculty of 
The Rockefeller University 
in Partial Fulfillment of the Requirements for 
































©  Copyright by Rohiverth Guarecuco Jr. 2021  
THE ROLE OF NUTRIENT AVAILABILITY IN THERAPEUTIC RESPONSE  
OF LEUKEMIA 
Rohiverth Guarecuco Jr., Ph.D. 
The Rockefeller University 2021 
 
Tumor environment influences the response to anti-cancer therapy, but which 
extracellular nutrients impact drug sensitivity is largely unknown. In this work, we used 
functional genomics to identify metabolic modifiers of the response to L-asparaginase 
(ASNase), a therapy that depletes plasma asparagine and targets leukemic cells with 
insufficient asparagine synthesis.  
Our approach revealed thiamine pyrophosphate kinase 1 (TPK1), which converts 
vitamin B1 (thiamine) into the cofactor thiamine pyrophosphate (TPP), as a metabolic 
dependency under ASNase treatment. In glutamine-anaplerotic leukemia cells, we 
found that TPP availability enables asparagine synthesis from extracellular glutamine. 
Mechanistically, TPP is critical for the activity of alpha-ketoglutarate dehydrogenase 
(AKGDH), a TCA cycle enzyme that catalyzes a step in the overall conversion of 
glutamine to asparagine. When TPP availability is limiting for cell proliferation of TPK1 
KOs, ASNase sensitivity is significantly increased.  
Standard cell culture media formulations provide thiamine at a concentration that 
is ~100-fold higher than that observed in human plasma. While thiamine is generally not 
limiting for cell proliferation under standard culture conditions, a DNA-barcode 
competition assay identified a subset of leukemia cell lines that grow sub-optimally 
under lower, more physiological thiamine levels. These cell lines are characterized by 
low expression of SLC19A2, a high affinity thiamine transporter. Intriguingly, SLC19A2 
expression was necessary for not only optimal growth, but also for maintaining ASNase 
resistance, when standard media thiamine was lowered to the concentration of human 
plasma.  
Importantly, analyzing RNAseq data of pediatric acute lymphoblastic leukemia 
(ALL) tumor samples revealed that SLC19A2 is the primary thiamine transporter 
expressed in these cancers, and that SLC19A2-low tumors exist among patients. To 
model such tumors, we used a SLC19A2-low cell line to generate orthotopic tumors in 
NSG mice. Remarkably, humanizing blood thiamine content of mice through diet 
sensitized these leukemia cells to ASNase in vivo.  
Altogether, our work reveals that utilization of thiamine is a determinant of 
ASNase response for some cancer cells, and that over-supplying vitamins may impact 
therapeutic response in leukemia. Additionally, our work adds to the recent literature 
that demonstrates how physiological levels of certain nutrients in cell culture can affect 
therapy. Specifically, our work provides the first proof of principle that humanizing the 
vitamin levels of both in vitro and in vivo models can affect drug sensitivity. This has 
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CHAPTER 1. Introduction 
 
 
1.1 Nutrient availability influences cellular metabolism and therapeutic response 
 
Nutrient availability in the tumor environment influences the metabolism of cancer cells, 
and may result in dependencies that can be exploited for therapy (1, 2). Indeed, 
deprivation of highly consumed extracellular nutrients in tumors may impose cancer 
cells to use specific metabolic pathways for proliferation and survival. For instance, low 
tumor glucose concentrations upregulate oxidative phosphorylation, an essential 
adaptation that can be targeted by the biguanide class of drugs (3). Similarly, 
environmental pyruvate and glutamine levels may determine the anaplerotic substrate 
cancer cells rely on (4). Interestingly, exogenous modulation of tumor nutrient supply 
can also affect metabolic programs, and consequently, therapeutic response (5). 
Through effects on one-carbon metabolism, histidine supplementation or dietary 
methionine restriction sensitizes cancer cells to commonly used chemotherapeutic 
agents (6, 7). The use of physiological cell culture media has further demonstrated that 
nutrient environment induces metabolic changes that affect drug sensitivity (8). In these 
recent studies, simply bringing media concentrations of uric acid and cystine to 
physiological levels altered cancer cell responses to 5-fluorouracil and CB-839, 
respectively (9, 10). Taken together, these examples illustrate the need for further 
investigation into which nutrients impact therapeutically-relevant metabolic pathways. In 
particular, it is poorly understood whether vitamins, which act as cofactors for many 
metabolic reactions, can affect responses to anti-cancer drugs. 
 
1.2 Specific vitamin dependencies in cancer and how they can be targeted 
 
Cancer cells may demonstrate increased dependencies on vitamins due to their need 
for particular vitamin-dependent reactions or because of defects in vitamin transport or 
activation. Vitamin B9, or folate, is a precursor for tetrahydrofolate, a coenzyme involved 
in enzymatic transfer of one-carbon groups in various amino acid and nucleic acid 
synthesis pathways collectively referred to as one-carbon metabolism. As many cancers 
rely on one-carbon pathways for proliferation (11), targeting one-carbon metabolism 
pathways with drugs such as methotrexate and 5-fluorouracile (5-FU) has been a 
successful strategy since the 1940s (12). 
 
Few reports have identified vitamin utilization defects such as impaired transport or 
inability to synthesize activated derivatives, defects that can be exploited 
therapeutically. In breast cancer cells, thiamine transporters (SLC19A2 and SLC19A3) 
have been found to be expressed at lower levels than their normal tissue counterparts. 
This led to the hypothesis that decreased thiamine transporter expression may make 
these cancers more dependent on exogenous thiamine, a vulnerability that can be 
targeted with acute thiamine starvation (13, 14). To circumvent the effects of chronic 
thiamine starvation, studies utilized a recombinant thiaminase enzyme that digests 
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thiamine and induces an acute thiamine depletion state (15). One subset of leukemias 
were more dependent on extracellular thiamine than other tested cell lines (15, 16). In 
follow-up studies, thiaminase was found to have in vivo efficacy against breast cancer 
and leukemia subcutaneous xenografts, as well as primary ALL cells injected 
intravenously (17). These thiaminase studies provide interesting examples of differential 
dependencies on extracellular vitamin levels possibly explained by varying degrees of 
vitamin transport capabilities. 
 
Another vitamin with reported heterogeneity in transporter expression across normal 
and cancerous tissues is riboflavin. Some riboflavin transporters were observed to be 
overexpressed in melanoma, breast cancer, and squamous cell carcinoma samples 
relative to healthy tissues (18). While these expression patterns may be useful for 
designing targeted drug-delivery systems, these findings may suggest the existence of 
cancers with increased riboflavin dependencies. It is also possible for cancers to have 
vulnerabilities in vitamin utilization downstream of extracellular uptake, such as in the 
enzymatic conversion of vitamins to activated derivatives. Examples include vitamin B6, 
an umbrella term for the 6 different vitamers that require different enzymatic steps for 
interconversion before yielding the activated cofactor form, pyridoxal phosphate (PLP) 
(19). Dependencies on exogenous pyridoxal (PL) or PLP forms of vitamin B6 have been 
observed in some tumors (20). Overall, with the exception of folate, there are promising 
but few reports on unique vitamin dependencies in cancer. Studying these 
dependencies could lead to dietary interventions or new therapeutic targets that could 
be as impactful as anti-folates have been for the last several decades. 
 
1.3 Acute lymphoblastic leukemia (ALL) 
 
1.3.1 Biology and pathophysiology 
 
Acute lymphoblastic leukemia (ALL) is a cancer of white blood cells (WBCs), primarily 
arising from cells of the B and T lineages. B-cell ALL represents ~85% of childhood and 
~75% of adult ALL cases, and T-cell ALL makes up the majority of the remaining cases 
in both age groups (21, 22). As a hematologic malignancy, the disease affects blood 
and lymph nodes, as well as bone marrow, where WBCs are originally produced. The 
most common presenting symptoms reflect these disease sites, and include blood 
abnormalities such as anemia and bleeding, lymph node involvement appearing as 
lymphadenopathy or hepatosplenomegaly, and bone pain due to marrow colonization 
(23). Since the involvement of both blood and lymphoid organs can result from the 
same initial white blood cell cancer, recent classification guidelines recognize these 
leukemias and lymphomas as a single disease that may also be referred to as acute 
lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). For simplicity, the 
remainder of this thesis will use the more established and widespread term “ALL”. 
 
The majority of ALL cases arise spontaneously with no known cause, but some 
environmental and genetic factors have been associated with an increased risk of ALL 
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occurrence (22, 24). Exposure to ionizing radiation has been linked with ALL, but most 
studies that examine the influence of environmental factors on ALL incidence have 
yielded inconsistent results (25). Among genetic syndromes, Down’s Syndrome is most 
commonly associated with increased risk of ALL (24, 26). Additionally, germline 
mutations in ETV6, PAX5, and TP53 have been associated with rare familial ALL cases 
(27-32). Finally, genome-wide association studies have implicated multiple genes as 
having polymorphic variants that increase the risk of ALL, including ARID5B, CEBPE, 
and IKZF1, which are annotated as genes involved in B-cell progenitor transcriptional 
regulation and differentiation (33, 34). Some of these factors that increase ALL risk have 
prognostic and therapeutic significance. For instance, TP53 mutations and IKZF1 
alterations are notable for their associations with ALL subtypes that have poor 
outcomes, and patients with abnormalities in these genes are assigned to high-risk 
chemotherapy regimens (21, 24).   
 
In addition to the genetic factors that predispose individuals to ALL, there are many 
common genomic alterations that arise spontaneously during leukemic cell 
transformation. These alterations are also important for prognosis and are used for risk 
stratification and assigning therapy (21, 22). Among the most common cytogenetic 
changes are ETV6-RUNX1 rearrangements and hyperdiploidy, which each carries a 
favorable prognosis (21, 35, 36). In contrast, less common genomic features may be 
associated with poor prognosis, leading to augmented chemotherapy protocols, or 
targeted treatment if applicable. In patients with previously high-risk Philadelphia 
Chromosome-positive ALL (Ph-positive ALL), targeting BCR-ABL1 with the ABL-class 
tyrosine kinase inhibitor (TKI) imatinib led to improved outcomes (37-41). Additionally, a 
high-risk ALL subtype termed Ph-like ALL does not express BCR-ABL1 but does 
contain kinase-activating genomic rearrangements involving genes like ABL1, JAK2, 
and PDGFRB, and may benefit from ABL-class TKIs like imatinib as well as JAK 
inhibitors like ruxolitinib (42-48). Recently, the FLT3 overexpression observed in high-
risk ALL with rearranged KMT2A (also referred to as MLL) has been targeted with FLT3 
inhibitors, in preclinical and clinical settings (49-51). Of note, the use of targeted 
therapies in ALL is still in early stages, and the vast improvements in ALL outcomes in 
the last few decades are largely attributed to the fine-tuning of treatment regimens 
involving established chemotherapeutics (24). However, the positive clinical outcomes 
observed with targeted therapies thus far demonstrate the need for further investigation 
of whether ALLs of certain genotypes may benefit from specific medications.   
 
1.3.2 Epidemiology and outcomes 
ALL is the most common cancer in children, representing ~26% of new cancer 
diagnoses in patients of ages 0-14 (52). In the United States, this translates to ~3,000 
new childhood ALL cases every year (21, 24). Fortunately, survival rates for childhood 
ALL have increased steadily over the last few decades (24, 53, 54), and five-year 
overall survival for childhood ALL is currently ~90% (24, 55). However, there are also 
~3,000 adult ALL cases diagnosed annually in the United States, and adult ALL patients 
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are generally considered to be high risk cases with a worse prognosis (22, 24, 56). This 
is reflected in the 5-year overall survival for adult ALL, which has improved in the last 
decades but is still estimated to be ~40%, with lower survival rates observed in older 
populations (57-60). 
 
The increase in 5-year survival for childhood ALL over the years has been attributed to 
the introduction of multi-drug, multi-phase regimens in the 1960s and 1970s (61-63), the 
inclusion of treatments aimed at preventing relapse within the central nervous system 
(CNS) (64), and the continuous improvement of risk stratification practices used to place 
patients on appropriate regimens (24, 63). Furthermore, the recent improvements in 
outcomes for adult ALL patients are associated with adapting successful pediatric 
protocols for use in adult patients (65-67). Although pediatric treatment regimens have 
proven effective in both children and adults, the survival rates for both childhood and 
adult ALL demonstrate that a significant number of patients in both age groups still fail 
these treatment protocols today. Thus, there is a need for continued research into not 
only new drug candidates, but also the improvement of existing ALL treatment protocols 
however possible.  
 
1.3.3 Risk stratification and treatment 
 
Although many factors have been evaluated for their importance in predicting ALL 
outcomes over the last few decades, only five are still routinely used for risk 
stratification: age, initial WBC count, leukemic cell cytogenetics and ploidy, immunologic 
subtype (B or T lineage), and initial treatment response (24, 63). Increased age, higher 
WBC count, certain cytogenetic features such as a BCR-ABL1 fusion, T-cell ALL, and 
persistence of disease after the first treatment phase are all indicators of a high-risk 
case (24). If a patient has high-risk characteristics, then standard multi-phase 
chemotherapy regimens may be augmented in terms of dose and frequency, or with 
additional medications (68, 69). Additionally, targeted treatments may be added for 
patients with specific cytogenetic characteristics. As stated above, patients with a BCR-
ABL1 fusion have a survival benefit with addition of the tyrosine kinase inhibitor (TKI) 
imatinib to standard therapy (39-41, 70), and to circumvent resistance or poor CNS 
penetration with imatinib, second- and third-generation TKIs have also been used with 
positive outcomes (71-77). Specific treatments have also been used recently for each 
immunologic subtype in refractory and relapsed cases. Blinatumomab is an antibody 
therapy that has produced survival benefits in advanced B-ALL (78-81), and nelarabine 
is a T-cell specific chemotherapy that has had success in refractory and relapsed T-ALL 
patients (82). However, allogeneic stem cell transplantation remains the gold standard 
for all refractory and relapsed ALL cases (22), and is beneficial for high-risk patients 
after completion of the initial phase of chemotherapy (83-86). 
 
Current treatment for standard-risk ALL patients involves multi-drug chemotherapy 
regimens, given as five phases of treatment that each last at least 1 month: induction, 
consolidation, interim maintenance, delayed intensification, and maintenance (24, 68). 
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Many of the medications and drug classes used in the initial induction and consolidation 
phases are used again in later phases, with possible substitution of certain drugs for 
another of the same class to further help eliminate residual drug-resistant cancer cells 
(Table 1). In standard pediatric regimens, the induction phase includes the 
chemotherapeutic vincristine, a corticosteroid such as prednisone, and the metabolism-
focused drug asparaginase (ASNase). In most cases, the induction phase causes a 
complete remission, but additional treatment phases are needed to prevent relapse 
(24). In the next treatment phase, consolidation, patients receive multiple 
chemotherapeutics that act by causing DNA damage or preventing DNA synthesis in 
proliferating cells (Table 1). Additionally, throughout these first two treatment phases 
and some of the subsequent phases, chemotherapies targeting DNA synthesis are 
administered directly into the spinal canal (24, 68). This is to prevent relapse of 
leukemia within the CNS, which would previously occur in the majority of patients who 
achieved complete remission with systemic chemotherapy (24, 64).  
 
 













Overall, the medications used in the various treatment phases of ALL are drugs that 
non-specifically target processes common to all proliferating cells, such as DNA 
synthesis. Interestingly, two of the therapies used in standard ALL treatment act by 
limiting the cellular availability of important metabolites. Methotrexate is a drug of the 
Drug Type Target 
cyclophosphamide chemotherapy DNA stability 
daunorubicin chemotherapy DNA stability 
doxorubicin chemotherapy DNA stability 
cytarabine chemotherapy DNA synthesis 
6-mercaptopurine chemotherapy DNA synthesis 
6-thioguanine chemotherapy DNA synthesis 
vincristine chemotherapy microtubule formation 
dexamethasone steroid various signaling pathways in WBCs 
prednisone steroid various signaling pathways in WBCs 
methotrexate DHFR inhibitor one-carbon metabolism 
L-asparaginase enzyme asparagine availability 
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antifolates class that inhibits dihydrofolate reductase (DHFR), the enzyme required for 
converting folate (vitamin B9) into tetrahydrofolate (THF), a folate derivative that is 
essential for DNA synthesis and other cellular processes (11, 12). L-asparaginase 
functions by depleting circulating levels of the amino acid asparagine, which forces 
leukemia cells to obtain sufficient intracellular asparagine for proliferation via 
mechanisms other than uptake (87, 88). Interestingly, the nutrient environment has 
been shown to influence leukemic cell responses to both methotrexate and ASNase. 
 
1.3.4 Nutrient supplements affect components of ALL therapy 
 
Folic acid, a synthetic conjugate base of folate, is readily available as a dietary 
supplement (89). For decades, some clinicians have advised against folic acid 
supplementation during methotrexate treatment of ALL (89-91). This advice stems from 
several observations. First, in the 1940s, Sidney Farber and his colleagues reported 
that administration of folic acid conjugates accelerates pediatric leukemia (92). This 
observation led to the seminal study that demonstrated the antifolate aminopterin (later 
replaced by methotrexate) could cause temporary remission of childhood leukemias 
(93). In addition to its growth-promoting effect in leukemia, supplemental folate has also 
been shown to interfere with leukemic cell uptake of methotrexate (94, 95). Finally, 
folate competes with methotrexate for the enzyme folypolyglutamate synthase that is 
required to produce polyglutamylated derivatives of these compounds, and 
polyglutamylated methotrexate has greater intracellular retention than methotrexate and 
contributes significantly to cytotoxicity (90, 91, 96).   
 
In cells, folate is metabolized into various derivatives, including folinic acid (5-formyl-
THF), a compound that is available as both a commercial vitamin supplement and as 
the chemoprotective medication leucovorin (90). Although folic acid supplements are 
not recommended during methotrexate treatment, folinic acid is used in the form of 
leucovorin to rescue toxicity in normal tissues by administration at adequate time-points 
following methotrexate treatment (90). Folinic acid is formed downstream from the 
DHFR reaction inhibited by methotrexate, and can be converted to THF for use in 
cellular metabolic reactions (89, 97). Thus, in multiple mouse and cell culture studies, 
folinic acid reversed the anti-cancer effects of methotrexate when administered 
simultaneously (90). As folinic acid is readily available as a nutritional supplement, 
patients must be advised against taking these supplements without clinician oversight, 
as dosage and timing may affect methotrexate treatment (90).  
 
Recently, exogenous supplementation of the amino acid histidine was shown to 
increase methotrexate sensitivity of leukemic cancer cell lines in vivo (6). Histidine 
catabolism utilizes THF, and increasing the flux of histidine into this degradation 
pathway depletes the cellular THF pools that are already in limited supply during DHFR 
blockade by methotrexate (6). Thus, along with folic acid and folinic acid, histidine is 
now one of the known readily-available nutritional supplements that can influence 
methotrexate response of leukemia cells.  
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Of the other medications used in standard ALL treatment, ASNase stands out as 
another therapy whose efficacy can be influenced by environmental nutrient availability 
(98, 99). However, exactly which extracellular metabolites affect ASNase sensitivity 
remains poorly understood. 
 
1.4 Leukemic cell response to L-Asparaginase (ASNase) 
 
L-asparaginase (ASNase) is a first-line chemotherapeutic for acute lymphoblastic 
leukemia (ALL) that depletes the amino acid asparagine from blood, thereby targeting 
leukemia cells that are unable to synthesize sufficient asparagine (87, 88). ASNase is 
unique among ALL therapies in that it exploits a specific metabolic vulnerability, 
observed several decades ago. The history of ASNase in cancer treatment dates back 
to the 1950s, when John Kidd first discovered that administering guinea pig serum to 
mice harboring transplanted lymphomas, or rats harboring transplanted 
lymphosarcomas, caused the cancers to regress (100, 101). In the early 1960s, J.D. 
Broome brought to light the observation that L-asparaginase is abundant in serum of 
guinea pigs but not other mammals, a phenomenon that had first been reported in the 
1920s (102, 103). In a series of experiments, Broome then demonstrated that the L-
asparaginase component of guinea pig serum was indeed responsible for its therapeutic 
effect (102, 103). ASNase was subsequently purified from E. coli and used in multiple 
clinical studies beginning in the late 1960s, in which it successfully treated ALL even as 
a monotherapy (104-107). Today, ASNase is a component of standard multi-agent 
treatment protocols for ALL. Unfortunately, as reflected in the current outcomes for 
childhood and adult ALL, not all patients respond to contemporary ASNase-containing 
regimens. Furthermore, the determinants of ASNase response in ALL remain 
incompletely understood. 
 
Major determinants of ASNase sensitivity include basal expression of asparagine 
synthetase (ASNS), a key enzyme that converts aspartate to asparagine, as well as the 
capacity to upregulate ASNS through ZBTB1 and activating transcription factor 4 
(ATF4) (108, 109). Recent work has identified alternative ways of increasing asparagine 
availability, such as through proteasome degradation (110) or aspartate uptake by 
solute carrier family 1 member 3 (SLC1A3) (111). Additionally, other cell types can 
secrete asparagine or its precursors, which ALLs can utilize, attenuating ASNase 
cytotoxicity (98, 99). These latter studies are particularly interesting because they 
exemplify that environmental nutrient availability can affect ASNase response of ALL 
cells. It remains unclear, however, whether extracellular nutrients that are not 
asparagine precursors can influence sensitivity to ASNase. 
 
1.5 Overview and Significance of findings 
 
Using a CRISPR/Cas9-based genetic screen, here, we interrogated the metabolic 
determinants of ASNase sensitivity in leukemia. Our analysis pinpointed thiamine 
pyrophosphate kinase 1 (TPK1) as essential for proliferation under ASNase treatment. 
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TPK1 converts thiamine to thiamine pyrophosphate (TPP), a cofactor necessary for the 
activity of the alpha-ketoglutarate dehydrogenase (AKGDH) complex. In glutamine-
anaplerotic leukemia cells, TPP availability enables asparagine synthesis from 
extracellular glutamine, when asparagine is depleted. We further identified that 
physiological levels of thiamine do not limit cell proliferation or ASNase resistance in 
most cancer cell lines, except for those that have low expression of SLC19A2, a 
thiamine transporter. These cancer cell lines become sensitive to ASNase when 
thiamine concentration is lowered to human plasma levels, which is ~100-fold lower 
than standard culture conditions. Consistent with this observation, a diet that humanizes 
mouse plasma thiamine levels sensitized leukemia xenografts with endogenously-low 
SLC19A2 to ASNase. Altogether, our results suggest that SLC19A2 expression may be 
a determinant of ASNase response and that supra-physiological thiamine 
supplementation could potentially ablate such an association. Furthermore, our work 
provides a proof of concept that using human physiological vitamin levels can affect 




CHAPTER 2. Metabolic determinants of proliferation under ASNase treatment 
 
 
2.1 In vivo ASNase responses of 62 cancer cell lines using a barcode-based 
competition assay 
 
To simultaneously test the responses of several cell lines to ASNase treatment, I first 
worked on expanding a previously reported barcoded cell line library that allows for cell 
competition assays under nutrient deprivation conditions (3). By inserting one or more 
permanent DNA barcodes into a cell line, the response of that cell line can be tracked 
through an experiment in which a pool of barcoded cell lines are grown together in a 
single vessel. By comparing responses in a vessel with replete medium to responses in 
a vessel containing a single nutrient depletion, we can screen for cell lines that may be 
resistant or sensitive to that particular nutrient depletion. These results can then be 
validated using individual cell line proliferation assays. This technique was first used to 
test responses of 28 cell lines to low glucose (3). Since the initial publication of this 
technique, our lab has continued to barcode cell lines, and we now have over 60 cell 
lines that can be included in a single competition experiment. 
 
Our expanded library of barcoded cell lines is largely composed of diverse subsets of 
leukemias and lymphomas, but also includes several myelomas, as well as smaller 
subsets of cell lines from epithelial malignancies such as breast, lung, and GI cancers. 
Each cell line has been infected with a lentiviral pool carrying 3 different DNA barcodes, 
and each barcode consists of a 7-nucleotide DNA sequence. When genomic DNA is 
extracted from a pool of barcoded lines, each of the 3 barcodes for a line is PCR 
amplified during preparation for deep sequencing, allowing for triplicate measures of 
each cell line in the competition assay. Barcoded cell lines are first cultured 
independently until the competition assay. To begin a competition experiment, the 
barcoded lines are pooled in approximately equal proportions. An initial aliquot is then 
taken, to be used for determining the initial distribution of barcodes in the pool. Another 
aliquot can then be placed into a vessel containing a control medium, or various vessels 
that each contain the same medium but with a particular nutrient missing (Figure 2.1). 
After ~2 weeks, aliquots are taken from the control and experimental vessels. Deep 
sequencing of the initial, control, and experimental samples allows us to see how the 





















Figure 2.1. Barcode-based competition assays for systematically mapping cancer 
nutrient dependencies. 
 
As multiple wild-type cell lines are known to be sensitive to asparagine depletion due to 
insufficient expression of ASNS (108), we hypothesized that cancers may have diverse 
responses to depletion of other non-essential amino acids as well. Thus, we attempted 
to validate our large barcoded cell line library in vitro in a set of custom RPMI medias 
that were each depleted in one non-essential amino acid. These flasks were cultured for 
14-18 days, after which all flasks had undergone ~10 population doublings, and the 
experiment was then processed for deep sequencing.  
The results of this experiment are presented in Figure 2.2. During analysis of our data, it 
was particularly informative to see which cell lines were represented in the sequencing 
reads of the initial pool but not in the control or experimental pools. The growth rates of 
these cell lines were likely too slow relative to other cell lines in these competitions, as 
they were not represented even in the control condition after ~10 population doublings. 
Thus, we could not obtain data for how these cell lines respond to nutrient depletions, 
and we filtered these cell lines out of our pipeline, leaving 49 cell lines with robust 
sequencing data for our final analysis. Notably, all of our ALL cell lines known to be 
sensitive to asparagine depletion were filtered out during our analysis due to this type of 
lack of representation in our control condition that suggested poor growth within 
competitions. However, analyzing the data for other cell lines passing our filters did 

















Figure 2.2. Validation of a blood and lymphoid cancer barcoded-based cell 
competition assay. 
(Top) Heatmap of barcoded cell line responses to various amino acid deprivation 
conditions. Data presented is the Log2 fold change in abundance from initial pool, of 
barcodes (n=3) representing indicated cell lines in the competition assay, relative to the 
control media condition.  
(Middle) Barcoded cell line responses to serine depletion (mean ± SD, n=3 barcodes).  
(Bottom-Left) Fold change in cell numbers (Log2) of a panel of wild-type cell lines used 
in our barcoded competition experiment, after individual growth assays in various serine 
concentrations for 5 days (mean ± SD, n=3). 
(Bottom-Right) CCLE RNAseq expression levels of indicated genes involved in serine 
synthesis. 
 
For instance, simultaneous deprivation of aspartate and glutamate in one vessel, or of 
proline and hydroxyproline in a different vessel, both had no discernible effects on cell 
proliferation across all cell lines. In contrast, low glutamine, low tyrosine, and complete 


















































































































































































































































































































































































































































































































competitions. Interestingly, there have been multiple recent reports on using 
serine/glycine-depleted diets to slow the growth of cancers (112). We were intrigued by 
the possibility that such diets could be used to treat some of the cancers that were 
sensitive to serine depletion in our competition assay. Thus, we attempted to validate 
our competition assay data for serine depletion by conducting independent proliferation 
assays under serine depletion using a panel of cell lines. 
Using a panel of 10 cell lines, we confirmed the existence of 5 cell lines that were 
resistant to serine depletion and 5 lymphoma cell lines that were sensitive (Figure 2.2). 
Whereas 2 sensitive cell lines arrested in serine-depleted media (U937 and DEL), 3 cell 
lines strikingly underwent substantial cell death (KARPAS299, SUPM2, and SUDHL4). 
We next looked at CCLE RNAseq data of these cell lines to determine whether low 
expression of any particular gene involved in serine synthesis could explain these 
growth responses to serine limitation. We found that KARPAS299, SUPM2, and 
SUDHL4 had very low PHGDH mRNA expression levels. Interestingly, the sensitivities 
of DEL and U937 to serine depletion were not explained by low CCLE expression of 
genes known to be involved in serine synthesis, including PHGDH, PSAT1, PSPH, 
SHMT1, or SHMT2. It is intriguing to consider why DEL and U937 are sensitive to 
extracellular serine depletion despite normal basal expression of serine synthesis 
pathway genes. One possibility is that these cell lines simply have a greater demand for 
serine than other cell lines and that this demand cannot be met by intracellular 
synthesis alone. If this is the case, then under serine limitation, the serine pools in these 
cells may be insufficient for carrying out processes required for cell proliferation. For 
example, if a cancer cell had a defect in glycine transport, then sufficient intracellular 
serine may be needed for not only incorporating serine into new proteins but also for 
maintaining glycine synthesis, as glycine is also required for protein synthesis as well as 
for synthesizing purines (11). Ultimately, further work is needed to determine whether 
DEL and U937 have specific metabolic vulnerabilities or demands that render them 
particularly sensitive to serine limitation. 
 
Of translational interest, we found that the CCLE data actually had several other 
lymphoma cell lines with PHGDH levels that predict serine auxotrophy according to our 
results. Interestingly, recent evidence showed that progression of in vivo lymphoma 
models can be slowed using serine/glycine-depleted diets (112). We considered 
whether the cancers represented by our serine auxotroph lymphoma cell lines could be 
targeted with low serine/glycine diets, but noted that published serine/glycine-free diets 
result in a circulating plasma serine concentration of ~50 µM instead of a true serine-
depleted environment. In our data, the lymphoma cell lines found to be serine 
auxotrophs can proliferate substantially at a media serine concentration of 30 µM. This 
suggests that targeting such lymphomas in vivo may require the use of alternative 
methods to achieve extracellular serine depletion, such as a serine-depleting enzyme 
analogous to L-asparaginase.  
 
Our experiments involving serine depletion validated that our barcode-based 
competition assay allows us to identify cancers that are resistant and sensitive to 
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deprivation of a single amino acid. Furthermore, coupling this barcoding technique with 
transcriptomics can help identify major genetic determinants of these growth responses, 
as in the case of low PHGDH predicting serine auxotrophy. However, we were not able 
to obtain a complete cell line sensitivity spectrum for L-asparaginase using this 
technique in vitro, because many ALL cell lines appeared to grow too slowly in vitro for 
sufficient barcode representation to remain even under control conditions at the end of 
the competition assay. As in vitro growth rates of cell lines do not always predict in vivo 
growth rates, we wondered whether these ALL cell lines could grow sufficiently in vivo 
relative to our other barcoded cell lines such that an in vivo competition assay would be 
possible. Furthermore, although ASNS expression is known to be a major determinant 
of ASNase sensitivity, it remains unclear whether ASNS expression perfectly predicts in 
vivo response to ASNase (113).  
 
We determined that in vivo competition assays with our large barcoded cell line library 
can be performed similarly to our in vitro competitions but with slight modification. Our 
pool of barcoded cell lines can be injected as multiple subcutaneous tumors in NSG 
mice, and mice can be divided into groups of control mice and mice treated with a drug 
of choice such as ASNase. After 2 weeks of tumor growth, we harvest the tumor 
xenografts, extract DNA from them, and process the DNA for sequencing as previously 
described for our in vitro competition assays. One important output of this type of 
experiment is the xenograft growth of these cell lines relative to each other. Some cell 
lines have low reads across all tumors, and these are filtered out from the final analysis, 
similarly to how we have to exclude slow growing cell lines in in vitro assays. However, 
in contrast to what we observed in control flasks of our in vitro experiments, many of the 
barcodes for ALL cell lines in our library are still represented in control tumors at 












Figure 2.3. In vivo barcode-based cell competition assay for ASNase responses.  
(Left) Schematic outlining cell line competition assay.  
(Right) Inter-tumor correlation of individual cell line responses (gray dots) observed in 
two independent tumors from the vehicle-treated group of the in vivo competition assay.  
 
 
Thus, to map in vivo ASNase responses, we used our pool of barcoded cell lines to 
generate subcutaneous xenografts in mice treated with either vehicle or ASNase 
(Figure 2.3). Our final analysis showed good inter-tumor correlation for the responses of 
62 cell lines (Figure 2.3). During our experiment, we harvested plasma from both mice 
groups. LC/MS profiling of plasma suggested that asparagine was the only depleted 
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Figure 2.4. Plasma profiling of mice treated with ASNase regimen.  
Relative abundance of indicated amino acids detected in plasma of mice on chow diet 
5B1Q, treated with vehicle (gray) or 1000 U/kg ASNase (orange) daily during in vivo 
competition assay. Plasma was collected after the first 2 days of treatment, 24h after 
last dose (n=5 mice per treatment, mean ± SD). nd: asparagine was not detected in 4 of 
5 ASNase-treated mice. Other measured amino acid levels, including that of glutamine, 
were unaffected by ASNase treatment. 
 
 
While most cancer cell lines did not respond to ASNase treatment, this competition 
assay revealed a set of cell lines as strongly sensitive to it. Consistent with previous 
work (114), many of these lines belong to ALLs that express low levels of ASNS mRNA 
(Figure 2.5). Although it is known that ALLs can be extremely sensitive to ASNase, it 
was striking to see that across all the cancers tested in our barcoded library, ALL 
remains the only cancer enriched at the ASNase-sensitive end. Despite the evidence 
that ASNS expression is a reasonable predictor for ASNase response, we found cancer 
cell lines with high expression of ASNS that appeared to have some sensitivity to 
ASNase treatment in vivo, whereas some with low expression appeared resistant. For 
instance, the chronic myeloid leukemia (CML) cell line BV173 was one of the 6 most 
sensitive cell lines, despite having middle to high ASNS expression. To contrast, the 
ALL line REH and the CML line EM2 had quite low ASNS expression but were not 
sensitive to ASNase. Overall, these data demonstrate that our large library of barcoded 
cell lines can be applied towards in vivo competition assays in order to systematically 
map cancer responses to therapies or nutrient depletions. Furthermore, data from these 
experiments can also be coupled with mRNA expression data to interrogate 
determinants of assay response. Importantly, our results with this barcoded competition 
assay system suggest that there may be factors other than ASNS that impact in vivo 
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Figure 2.5. ASNS expression is a reasonable, but imperfect, predictor of in vivo 
ASNase sensitivity across hematopoietic and lymphoid cancer cell lines. 
Log2 fold change in abundance from initial pool, of barcodes (n=3) representing 
indicated cell lines in the competition assay, for ASNase-treated tumors (n=10) relative 
to mean of vehicle-treated tumors (n=10). Boxes represent the median, and first and 
third quartiles, and whiskers represent the minimum and maximum of all data points. 
Statistics: FDR-adjusted P, by two-tailed unpaired t-test for unequal variances, of 
ASNase tumor group versus vehicle tumor group. Individual CCLE RNAseq ASNS 
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2.2 CRISPR-based screen identifies metabolic genes whose loss sensitizes cells 
to ASNase 
 
To further investigate the metabolic determinants of ASNase response, we performed 
metabolism-focused CRISPR/Cas9-based screens in Jurkat, a T-ALL cell line resistant 
in our in vivo competition assay (Figure 2.6). Consistent with the essential role of 
asparagine synthesis under asparagine depletion, our screens yielded ASNS as the top 
scoring gene, with 6 out of 8 ASNS guides differentially depleted under ASNase 










Figure 2.6. CRISPR-based screen for metabolic determinants of ASNase 
response. 
(Left) Schematic depicting pooled CRISPR screen under ASNase treatment (0.25 
U/mL) using a metabolism-focused sgRNA library.  
(Right) Gene scores for Jurkat cells grown in untreated versus ASNase-treated vessels. 
Most genes, as well as non-targeting control sgRNAs, gave similar scores in untreated 


























In addition to ASNS, we noted scoring of TCA cycle genes fumarate hydratase (FH) and 
malate dehydrogenase 2 (MDH2), as well as glutamic-oxaloacetic transaminase 2 
(GOT2), highlighting a route to aspartate, the substrate for ASNS and precursor of 
asparagine (Figures 2.7, 2.8, and 2.9). Furthermore, sgRNAs targeting solute carrier 
family 1 member 5 (SLC1A5), the major glutamine transporter, and solute carrier family 
25 member 12 (SLC25A12), a mitochondrial glutamate/aspartate exchanger, were also 
significantly depleted under ASNase treatment (Figure 2.6). Since many cancers use 
glutamine as a major anaplerotic source (115), our results confirm that the pathway 
from glutamine uptake to asparagine synthesis through the oxidative TCA cycle is 





















































































Figure 2.8. CRISPR screen guide scores for top scoring genes. 
Log2 fold change in the abundance of individual sgRNAs in untreated (black) or 
ASNase-treated (gray) for the following top scoring genes in our CRISPR screen: 
















Figure 2.9. Top scoring genes in CRISPR screen highlight a specific route from 
glutamine to asparagine as essential under ASNase treatment. 
 
Interestingly, the second top-scoring gene in our screens was TPK1, for which all 8 
guides were differentially depleted when we treated cells with ASNase (Figures 2.7 and 
2.8). TPK1 is a ubiquitously expressed cytosolic kinase that uses imported thiamine and 
ATP to produce TPP, the thiamine derivative that serves as a cofactor for many 
enzymes, including AKGDH in the TCA cycle (116). To our surprise, TPK1, though 
predicted to be a cell-essential gene, did not score under standard culture conditions, 
suggesting the presence of sufficient TPP for proliferation. Given the lack of any 
previous connection between thiamine metabolism and ASNase response, we next 
























3.1 TPK1-null cells are sensitized to ASNase treatment when supplemental TPP is 
limiting 
 
To understand how TPK1 loss sensitizes leukemia cells to ASNase, we generated 
CRISPR/Cas9-mediated clonal knockouts of TPK1, in which TPK1 protein levels were 
undetectable (Figure 3.1). Interestingly, unlike in our genetic screening conditions, 
TPK1 null Jurkat cells die in culture unless supplemented with TPP. This suggests that 
TPP is indeed essential for proliferation, and that TPP from other cells with functional 
TPK1 may have fueled the growth of TPK1 null cells during the course of the genetic 
screens. To determine whether TPP limitation is sufficient to sensitize Jurkat cells to 
ASNase, we first determined a TPP dose that enabled sub-optimal proliferation of TPK1 
null cells under standard culture conditions (2.5 nM). At this dose, TPK1 null cells were 
significantly more sensitive to ASNase treatment compared to parental controls (Figure 










Figure 3.1. Effect of TPP availability on ASNase sensitivity in TPK1 KOs. 
(Top) Immunoblot analysis of Vector Control and two clonal TPK1 knockouts made from 
Jurkat cells. GAPDH was used as a loading control.  
(Bottom) Fold change in cell number (log2) of Vector Control, TPK1_KO1, and 
TPK1_KO2 Jurkat cells, after untreated or 0.0005 U/ml ASNase conditions for 5 days 
(mean ± SD, n=3). Statistics: P < 0.05 by two-tailed unpaired t-test for equal variances, 
for all 15 untreated-treated pairs. 
 
Overexpressing sgRNA-resistant TPK1 cDNA rescued both TPP-dependency and the 
TPP-dependent ASNase sensitivity of TPK1 null cells (Figure 3.2). Altogether, these 
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Figure 3.2. Overexpression of sgRNA-resistant TPK1 cDNA rescues TPP-
dependence and TPP-dependent ASNase sensitivity of TPK1 KOs. 
(Top) Immunoblot analysis of Vector Control, TPK1 knockout, and cDNA-rescued TPK1 
knockout Jurkat cells. GAPDH was used as a loading control. 
(Bottom) Fold change in cell number (log2) of cDNA-rescued TPK1 knockout Jurkat 
cells, compared to that of cDNA-expressing Vector Control cells generated in parallel 
and that of wild-type cells, after untreated or 0.0005 U/ml ASNase conditions for 5 days 
(mean ± SD, n=3). Statistics: P < 0.05 by two-tailed unpaired t-test for equal variances, 
for all 20 untreated-treated pairs. 
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3.2 TPP allows asparagine synthesis from glutamine under extracellular 
asparagine depletion 
 
TPP is used as a cofactor by various enzyme complexes, including the a-ketoglutarate 
dehydrogenase complex (AKGDH), which catalyzes the oxidative decarboxylation of a-
ketoglutarate in the TCA cycle along the pathway from glutamine to asparagine. To 
directly determine whether de novo asparagine synthesis from glutamine requires TPP, 
we measured the generation of TCA cycle intermediates, aspartate, and asparagine 
from uniformly heavy carbon labeled glutamine ([U-13C]-L-glutamine), in the presence 
or absence of TPP and asparagine. We performed this in parental and TPK1 null Jurkat 

















Figure 3.3. [U-13C]-L-glutamine tracing in TPK1 KO cells and cDNA-rescued 
counterparts in the presence and absence of TPP and asparagine. 
(Top-Middle) Schematic depicting a metabolic route of asparagine synthesis from 
glutamine. Filled circles represent 13C atoms derived from [U-13C]-glutamine.  
(Rest) Abundance of indicated metabolites derived from labeled glutamine in Vector 
Control, TPK1_KO1, and cDNA-rescued TPK1_KO1 Jurkats. Cells were incubated for 
24 hours in media containing [U-13C]-glutamine (2 mM) in the presence or absence of 




In asparagine replete conditions, we did not detect any asparagine labeling, indicating 
the lack of asparagine synthesis. In contrast, when asparagine was absent, ~50% of the 
asparagine in parental cells, and TPK1 null cells supplemented with TPP or expressing 
TPK1 cDNA, was derived from oxidative metabolism of [U-13C]-L-glutamine, in line with 
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and TPP, we observed a substantial decrease in total as well as oxidatively labeled 
(m+4) malate, aspartate, and asparagine in TPK1 null cells. Addition of TPP or 
expression of TPK1 cDNA rescued all decreases in these metabolite levels. Strikingly, 
TPK1 loss also led to the massive accumulation of alpha-ketoglutarate. Together with 
the depletion of metabolites downstream from alpha-ketoglutarate, this is consistent 
with the cofactor role of TPP for the AKGDH complex. Altogether, these metabolite 
profiling data were in line with our genetic screen data by highlighting that utilization of 
glutamine for the oxidative TCA cycle is essential for asparagine synthesis under 
exogenous asparagine limitation in Jurkat cells. Furthermore, these results suggest that 
by enabling AKGDH activity in the TCA cycle, TPP allows asparagine synthesis from 




CHAPTER 4. Physiological thiamine is limiting for growth and ASNase response 
of low SLC19A2 leukemia cells 
 
 
4.1 Barcode-based competition assay identifies cell lines that grow sub-optimally 
at low, physiologically-relevant thiamine concentrations 
 
Given that thiamine-derived TPP availability enables growth under ASNase treatment, 
we considered that conventional RPMI 1640 (RPMI) medium provides supra-
physiological thiamine by supplying it at 3 µM. This is approximately 100-fold the 
content of normal human plasma, which ranges from 6.6 to 43 nM (117). Building upon 
the observation that TPK1 null cells display increased ASNase sensitivity under limiting 
TPP concentrations, we explored two questions: first, that physiological thiamine levels 
may be a growth limitation for a subset of cancer cell lines; and second, that culturing 
such a subset in limiting thiamine environments may impact ASNase responses. To 
address our first question, we decided to perform cell line competition assays in RPMI, 
with and without added thiamine (supplemented with 10% dialyzed FBS). Notably, the 
trace thiamine in dialyzed FBS leads to ~1 nM total thiamine in culture, which 
approximates the content of human plasma.  
 
As noted in Chapter 2, once individually-cultured barcoded cell lines have been pooled 
together, this pool can be divided into many different conditions of interest. Although we 
intended to focus on finding cancer cell lines for which the lower thiamine 
concentrations of human plasma may be limiting, we decided to simultaneously test 
responses of our barcoded cells to other vitamin limitations. Our rationale was an 
unbiased one: we did not know beforehand whether any vitamin deprivation condition 
could be limiting for some cancers while not affecting others, and testing multiple 
conditions gave us an answer this question. Thus, rather than make only a control 
medium and a low thiamine medium to grow barcoded pools in, I systematically made 7 
custom RPMI medias that were each missing a single water-soluble vitamin normally 
contained in RPMI. This was done by using the same base medium for each condition, 
and by adding all but one vitamin to this base medium.  
 
Although vitamins are essential nutrients for cell viability and growth, circulating human 
blood contains very low levels of some vitamins, as exemplified by human plasma 
having thiamine in the nanomolar range. These low levels of vitamins are still sufficient 
for cellular metabolism and growth, likely because most vitamins are metabolized into 
derivatives that serve as enzymatic cofactors rather than as cellular building blocks. 
When we conducted barcoded competition assays in amino acid depletion conditions, 
we had to note which amino acids were essential in culture. Conditions in which an 
essential amino acid was depleted had to contain supplemental levels of the amino acid 
that permitted mildly-inhibited cell proliferation. These supplemental amino acid 
amounts were in the micromolar range. In contrast, for our vitamin limitation 
competitions, we hypothesized that supplementation of media with even a dialyzed form 
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of FBS would provide the minuscule amounts of a depleted vitamin needed for cells to 
grow. We tested this in pilot experiments beforehand. Indeed, for most vitamins in 
RPMI, it is possible to completely remove the vitamin from RPMI and cells will still grow 
using the vitamin amount supplied solely by the supplemental dialyzed FBS. Thus, the 7 
custom RPMIs I made that were each missing a vitamin were each simply combined 
with 10% dialyzed FBS, and these were the final mediums used for cell competitions. 


















Figure 4.1. Barcode-based competition assay at conventional and lower, 
physiologically-relevant thiamine concentrations and under other vitamin 
depletions. 
(Top) Heatmap of barcoded cell line responses to various vitamin deprivation 
conditions. Data presented is the Log2 fold change in abundance from initial pool, of 
barcodes (n=3) representing indicated cell lines in the competition assay, relative to the 
control media condition.  
(Bottom-Left) Barcoded cell line responses to thiamine depletion (mean ± SD, n=3 
barcodes). Of note, cells were grown in the absence of thiamine (-thiamine), or in the 
RPMI concentration of 3 µM thiamine (+thiamine). Media were supplemented with 10% 
dialyzed FBS, which contributes ~1 nM thiamine. 
(Bottom-Right) Relative abundance of thiamine in RPMI (containing 3 µM thiamine), 
regular FBS (rFBS), and dialyzed FBS (dFBS) (mean ± SD, n=3), used to estimate the 
thiamine contribution of each FBS when combined with thiamine-free RPMI. 
 
The data for this systematic characterization of vitamin dependencies is presented in 
Figure 4.1. Interestingly, for many vitamin depletion conditions, no cell lines seemed to 
be affected by limitation of the vitamin. In fact, in low B12, low pantothenate, and low 
pyridoxine, cells behaved almost identically to how they grew in control medium. In low 










































































































































































































































































































































































































































these cells had a relative growth advantage in this condition. In contrast, in low biotin, 
low niacin, and low thiamine, we observed that subsets of cell lines seemed to drop out 
of the cell competitions. This was intriguing, as it generally suggested a remarkable 
heterogeneity among cancers in responding to low levels of these vitamins but not 
others in our experiment. It is possible that in conditions like low B12, low pantothenate, 
and low pyridoxine, the vitamin level was not low enough to affect cell proliferation. 
These vitamins are all essential for human cells, and a low enough extracellular 
concentration of these vitamins would likely slow proliferation. Our results suggest that 
the trace amounts of these vitamins supplied by dialyzed FBS in our experiments was 
actually sufficient to enable maximal cancer cell proliferation of all cell lines tested. It is 
interesting to consider that cancer cell lines had heterogeneous responses to low levels 
of certain vitamins. This could potentially be due to different vitamin transport 
capabilities among cancer cell lines. For instance, it is possible that the cell lines that 
were depleted in these competitions have low expression of high-affinity transporters of 
these vitamins. If this is the case, it’s possible these vitamins can enter cells through 
various low-affinity transporters under the excessive vitamin concentrations of RPMI, 
whereas a high-affinity transporter may be required for optimal proliferation in lower 
vitamin concentrations. Alternatively, it is possible that cell lines depleted in 
competitions rely more on a specific vitamin-utilizing pathway for proliferation compared 
to other lines. We know that inhibiting folate metabolism interrupts DNA synthesis, 
which is essential for cell proliferation. Similarly, it is possible that depleting biotin, 
niacin, or thiamine limits flux through one particular metabolic pathway that some 
cancers greatly depend on for proliferation.  
 
Of particular interest to us, many cancer cell lines grew similarly in control and low 
thiamine conditions, but the fact that a small subset was depleted in the competition 
assay specifically under low thiamine suggested that low thiamine content could limit 
proliferation of some cancers as we had hoped to find.  
 
We next determined whether the expression of any particular thiamine utilization gene is 
predictive of growth responses to thiamine limitation. Correlating growth in low thiamine 
with mRNA expression data of metabolic genes from CCLE revealed the plasma 
membrane thiamine transporter SLC19A2 as a top scoring gene (Figure 4.2). 
Expression of SLC19A3, the other canonical thiamine transporter, was not a predictor of 
growth under low thiamine, and low mRNA levels of SLC19A3 compared to SLC19A2 in 
CCLE (median TPM of 0.1 vs 6.6) suggested SLC19A2 may be the primary transporter 
















Figure 4.2. Expression of SLC19A2, but not SLC19A3, is a predictor of 
proliferation capacity at low thiamine. 
Low thiamine cell competition responses were correlated with CCLE mRNA expression 
data of metabolic genes, and thiamine transporter 1 (SLC19A2), but not thiamine 
transporter 2 (SLC19A3), had one of the top scoring Pearson’s correlation coefficients. 
 
4.2 CRISPR-based screen identifies metabolic genes essential for proliferation in 
low thiamine 
 
To further support our competition assay results, we simultaneously performed a 
metabolism-focused CRISPR/Cas9-based genetic screen using Jurkat cells under the 
same low and high thiamine conditions. Similar to the correlation results from the cell 
competition assays, SLC19A2 was the top scoring gene, with 5 of 8 guides being 
selectively depleted in low thiamine media (Figure 4.3). Notably, additional genes with 
no known connections to thiamine uptake scored in our screen, suggesting that other 
metabolic dependencies exist when thiamine is low. Altogether, our unbiased 
competition assay and genetic screen approaches both pinpoint that SLC19A2 
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Figure 4.3. CRISPR-based screen for metabolic determinants of growth in low 
thiamine. 
(Left) Gene scores for a CRISPR screen done with Jurkat cells in the presence 
(+thiamine) or absence (-thiamine) of 3 µM thiamine. Media were supplemented with 
10% dialyzed FBS, which contributes ~1 nM thiamine. Most genes gave similar scores 
in the two conditions.  
(Middle) The top 10 genes differentially required in low thiamine are shown.  
(Right) Log2 fold change in the abundance of individual sgRNAs in our CRISPR screen, 
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4.3 SLC19A2 expression is a determinant of not only growth, but also ASNase 
response, at physiological thiamine levels 
 
Given the connection between thiamine utilization and ASNase response, we next 
asked whether cell lines with low SLC19A2 are more sensitive to ASNase in limiting 
physiological thiamine than in the high thiamine of conventional media. To address this, 
we identified three B-ALL cell lines, KOPN8, REH, and NALM6, in which SLC19A2 
mRNA was undetectable, consistent with CCLE data (Figure 4.4). We had previously 
noted REH and NALM6 were ASNase-resistant in barcoded competitions in mice, but 
















Figure 4.4. Baseline mRNA levels by RT-qPCR of SLC19A2 in a panel of leukemia 
and lymphoma cell lines. 
Baseline mRNA levels by RT-qPCR of indicated genes for cell lines representing the 
following cancers: T-ALL (JURKAT), B-ALL (RCH-ACV, KOPN8, REH, NALM6), diffuse 
large B-cell lymphoma (SUDHL4), and Burkitt lymphoma (ST486). ND: not detected 
(mean ± SD, n=3). 
 
 
Consistent with the in vivo competition results, REH cells proliferated similarly in the 
presence and absence of ASNase under standard culture conditions (3 µM thiamine). 
However, under low thiamine (~60 nM) conditions, untreated cells indeed grew slightly 
less than at 3 µM (2 versus 4 doublings in 6 days) but now, strikingly, ASNase treatment 
severely impaired cell growth (no doublings in 6 days). Furthermore, overexpression of 
SLC19A2 was sufficient to rescue both the decreased growth of untreated cells and the 
increased ASNase response at ~60 nM thiamine (Figure 4.5). This suggests that 
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Figure 4.5. Lowering media thiamine sensitizes SLC19A2-low cells to ASNase, 
and this can be rescued by overexpressing SLC19A2 cDNA. 
Fold change in cell number (log2) of Vector Control and SLC19A2-cDNA-expressing 
REH cells, after untreated or 0.001 U/ml ASNase conditions for 6 days, in the presence 
(+) or absence (-) of 3 µM thiamine (mean ± SD, n=3). Media were supplemented with 
10% regular FBS, which contributes ~60 nM thiamine. P < 0.05 for all 4 untreated-
treated pairs. 
Statistics: two-tailed unpaired t-test for equal variances. 
 
 
Consistent with this, as we further lowered thiamine towards 10 to 40 nM to be within 
the human plasma range, we found that for SLC19A2-low REH and NALM6 cells, 
thiamine levels constrained growth and ASNase had a greater effect, compared to cells 
cultured in supra-physiological thiamine (Figures 4.6 and 4.7). At 10 nM thiamine, live 
REH cells were still visualized in ASNase-treated conditions (Figure 4.7). This is 
consistent with the REH data shown in Figure 4.6 in which cells appeared to arrest 
rather than die at 10 nM thiamine when ASNase-treated. Thus, at 10 nM thiamine, REH 
cells can proliferate when untreated but appear to undergo stasis when treated with 
ASNase. In contrast, SLC19A2-high Jurkat, RCH-ACV, and ST486 cells were 
unaffected by physiological thiamine concentrations, and their ASNase response was 
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Figure 4.6. SLC19A2 expression is a determinant of both growth and ASNase 
response at physiological thiamine in a panel of cell lines. 
(Top) Fold change in cell number (log2) of SLC19A2-high (Jurkat) and -low (NALM6, 
REH) wild-type cell lines, after untreated or 0.001 U/ml ASNase conditions for 7-9 days, 
at different thiamine concentrations added to thiamine-free RPMI supplemented with 
10% double-dialyzed FBS (mean ± SD, n=3). P < 0.05 for untreated-treated pairs at 
these thiamine concentrations: JURKAT- all concentrations, NALM6- all above 1.25 nM, 
REH- all above 0 nM. 
(Bottom) Independent experiment similar to that in (Top), showing fold change in cell 
number (log2) of additional SLC19A2-high (ST486, RCH-ACV) wild-type cell lines 
compared to SLC19A2-low NALM6, after untreated or 0.001 U/ml ASNase conditions 
for 7 days, at different thiamine concentrations added to thiamine-free RPMI 
supplemented with 10% double-dialyzed FBS (mean ± SD, n=3). Statistics: For NALM6 
only, P < 0.05 by two-tailed unpaired t-test for equal variances, for all 5 untreated-
treated pairs. 
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Figure 4.7. Bright-field micrographs of a SLC19A2-low cell line in the presence 
and absence of ASNase at high and low thiamine. 
Representative bright-field micrographs of the wild-type REH experiment in Figure 4.6, 
after untreated or 0.001 U/ml ASNase conditions for 9 days at the indicated thiamine 
concentrations added to thiamine-free RPMI supplemented with 10% double-dialyzed 




















































































































































Importantly, CRISPR-Cas9-mediated targeting of SLC19A2 in Jurkat, which decreased 
13C-labeled thiamine uptake, showed that SLC19A2 was necessary for cells to 
proliferate optimally and maintain ASNase resistance under human plasma thiamine 















Figure 4.8. Effects of CRISPR-mediated targeting of SLC19A2 on 13C-Thiamine 
uptake and ASNase sensitivity at physiological thiamine. 
(Top) 13C-thiamine uptake in Vector Control, sgSLC19A2_1, and sgSLC19A2_2 
expressing Jurkat cells (mean ± SD, n=3). 
(Bottom) Fold change in cell number (log2) of Vector Control, sgSLC19A2_1, and 
sgSLC19A2_2 expressing Jurkat cells, after untreated or 0.001 U/ml ASNase conditions 
for 5 days, at different thiamine concentrations added to thiamine-free RPMI 
supplemented with 10% double-dialyzed FBS (mean ± SD, n=3). P < 0.05 for all 15 
untreated-treated pairs. 
Statistics: two-tailed unpaired t-test for equal variances. 
 
 
Taken together, these data establish SLC19A2 expression as a determinant of (1) 
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CHAPTER 5. Dietary thiamine intake influences ASNase sensitivity of low 
SLC19A2 leukemia cells in vivo 
 
 
5.1 SLC19A2 is the only detectable thiamine transporter in patient ALL samples, 
and a subset of patients have low SLC19A2 tumors 
 
To confirm that endogenously-low expression of SLC19A2 in cell lines is not a tissue 
culture artifact, we probed for the existence of SLC19A2-low patient tumors. As ASNase 
is a standard in the initial treatment phase of ALL, we explored RNAseq data of 
pediatric primary ALLs sampled from peripheral blood and bone marrow, as well as 
























Figure 5.1. Patient RNAseq data from TARGET ALL Sub-study. 
RNAseq expression data for indicated genes, for various patient tumor samples from 
ALL Expansion Phase 2 Sub-study of TARGET, and for every cell line in CCLE 
(representing diverse tissue origins) for comparison. 
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ASNS, TPK1, and SLC19A2 mRNAs were consistently detected in these 3 datasets 
(Figure 5.1), and their expression was similar between primary and recurrent bone 
marrow datasets, suggesting that treatment generally did not influence mRNA levels of 
these genes. Of note, SLC19A3 mRNA was very rarely detected, indicating that 
SLC19A2 is likely the primary thiamine transporter expressed in these tumors, similar to 
that seen across CCLE cell lines. Importantly, these data show a diverse range of 
SLC19A2 expression among patients and confirm the existence of low SLC19A2 tumors 
in which ASNase response may depend on environmental thiamine. 
 
 
5.2 Humanizing blood thiamine of mice through diet sensitizes low SLC19A2 ALL 
cells to ASNase in vivo 
 
We next asked whether extracellular thiamine availability also affects ASNase response 
of SLC19A2-low leukemia cells in vivo. To create a model of such tumors, we used the 
SLC19A2-low REH cell line and generated orthotopic tumors in NOD-SCID gamma 
(NSG) mice. First, mice that were on the conventional chow-based diet used in our 
barcoded competition experiment were placed on a purified ingredients diet with either a 
high thiamine amount to mimic the supra-physiological plasma thiamine levels obtained 
with chow, or a low amount that resulted in levels resembling that of human serum 
(Figure 5.2, Table 5.1).  
 
Importantly, it is also possible to maintain supra-physiological blood thiamine levels in 
humans. In the clinic, supplemental thiamine is usually administered when thiamine 
deficiency is suspected. However, prophylactic use has been recommended for other 
scenarios, such as for preventing malignancy-associated thiamine deficiency (118, 119) 
or for cases of malnutrition such as patients struggling with alcohol dependency (120). 
There is no standard regimen for clinical thiamine supplementation even for cases of 
deficiency (120-122). In a study that evaluated thiamine supplementation regimens 
used in out-patient management of alcohol dependency, a total daily administration of 
500 mg thiamine by intramuscular or oral routes led to plasma thiamine levels ~10-fold 
and ~8-fold greater than normal levels, respectively (123). These regimens were given 
for 11 days, and these supra-physiological levels were maintained over the majority of 
this timeframe. Even higher plasma thiamine levels (~100-fold of normal) have been 
observed transiently after fast intravenous administration of less than 500 mg thiamine 
(117, 124), and intravenous regimens are recommended when deficiency is suspected 
(120-122). Of note, 500 mg thiamine tablets are commercially available for dietary 
supplementation, with suppliers recommending daily intake of these tablets. Thus, it is 
plausible to consider that supra-physiological plasma thiamine could be reached in a 
cancer patient not only through clinical prophylactic regimens aimed at preventing 
malnutrition, but also through consumption of readily-available dietary supplements. 
 
Lowering plasma thiamine to human levels was well-tolerated, as indicated by animal 
weights remaining unchanged after diet modification (Figure 5.2). We then engrafted 
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REH cells in mice on either high or low thiamine diets, and tested the efficacy of 
ASNase treatment in each of these cohorts. Importantly, our ASNase regimen depleted 
plasma asparagine levels without affecting the levels of abundant amino acids such as 
glutamine (Figure 5.3). 
 
 
Figure 5.2. Humanizing plasma thiamine levels in mice by lowering thiamine 
content of diet. 
(Left) Plasma thiamine profiling of mice on conventional chow (n=3 mice), and mice on 
a modified AIN-93G purified diet of low thiamine content (n=8 mice) (mean ± SD). 
Human serum was profiled simultaneously for relative comparison. Statistics: *P < 0.01 
by two-tailed unpaired t-test for unequal variances. 
(Middle) Weights of mice initially on conventional chow, then switched to standard AIN-
3G purified diet for 1 week, and finally switched to a modified AIN-93G purified diet of 
low thiamine content (n=8 mice) for indicated times, relative to initial weights on chow 
(mean ± SD). 
(Right) Plasma thiamine profiling of mice on conventional chow (n=4 mice), and mice on 
a modified AIN-93G purified diet of high thiamine content (n=4 mice) (mean ± SD). 

































Figure 5.3. Alternative ASNase regimen in mice with less frequent administration. 
Relative abundance of indicated amino acids detected in plasma of mice on purified diet 
AIN-93G containing high thiamine, before treatment (gray) and after 1000 U/kg 
ASNase. Plasma was collected after a single dose, at days 1 (orange) and 4 (pink) after 
administration (mean ± SD, n=3 mice), and because asparagine remained depleted 
after 4 days, mice were treated only twice weekly in the xenograft survival experiments. 
Of note, glutamine was not depleted at either time-point. 
 
 
Compared to the high thiamine diet group in which plasma thiamine was comparable to 
that seen with standard chow, neither ASNase treatment or lowering dietary thiamine 
alone significantly affected survival from leukemia (Figure 5.4). Of note, proliferation of 
these leukemia cells slowed under low thiamine conditions in vitro, raising the possibility 
that the in vivo microenvironment that cells were directly exposed to may not contain 
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treatment and low dietary thiamine did indeed significantly (Mantel-Cox P = 0.0034) 

















Figure 5.4. ASNase significantly increases survival of mice bearing orthotopic 
xenografts of an SLC19A2-low cell line, only when dietary thiamine is lowered. 
(Left) Kaplan-Meier survival curves of NSG mice on high or low thiamine AIN-93G diets 
engrafted with REH (endogenously-low SLC19A2 cell line) by tail-vein injection, and 
treated with vehicle or ASNase (1000 U/kg, twice per week).  
(Right) Box and whisker plots of survival data.  
Statistics: (Left) n.s. = Mantel-Cox P > 0.05 / 3 (Bonferroni correction), and (Right) n.s. = 
two-tailed unpaired t-test for equal variances P > 0.05 / 3 (Bonferroni correction). For 




Altogether, our results provide evidence that thiamine availability resulting from dietary 
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CHAPTER 6. Discussion 
 
In previous studies, a cell competition assay of 28 barcoded cell lines representing 
various cancer types had shown that growth of different cancers can vary greatly under 
nutrient limitations such as low glucose and low cholesterol (3, 125). In this work, I 
helped expand this library of barcoded cell lines by both lentivirally infecting more cell 
lines with barcodes and by validating that all cell lines in our final library had correctly 
annotated barcodes. This resulted in a comprehensive list of more than 60 barcoded 
cell lines, mainly representing cancers of hematopoietic and lymphoid tissues. Cancers 
of these origins were of particular interest to us, as leukemias such as ALLs have 
already been treated successfully in the past through the depletion of circulating 
nutrients. This is best exemplified by the clinical success of ASNase even as a 
monotherapy for ALL, and also by the more recent use of arginase for certain AMLs 
(126). Thus, it is possible that there may be other unknown, clinically-relevant nutrient 
dependencies still to be mapped among cancers of blood and lymphoid origins. 
Importantly, we validated that our large barcoded cell line library could indeed be used 
for in vitro cell competitions, but also for in vivo competitions by injection of barcoded 
pools as subcutaneous xenografts in mice. This methodology can now be applied not 
only towards mapping responses to nutrient deprivation conditions, but also towards 
testing novel drug treatments across these cancer cell lines.  
 
Here, we first applied our barcoded cell line assay towards a systematic mapping of 
cancer cell responses to the depletion of individual non-essential amino acids (NEAAs) 
in vitro. To do this, we simultaneously made 9 custom RPMI medias, where each was 
missing only 1 or 2 NEAAs, and grew barcoded pools under these different conditions. 
In our assays, there were some conditions in which no cell lines were affected, such as 
in aspartate/glutamate-free media, as well as in proline/hydroxyproline-free media. In 
contrast, we observed that in low tyrosine, low glutamine, and complete serine 
depletion, a subset of barcoded cell lines proliferated less than in control conditions. 
This raised the possibility that some of these cancers could be targeted by limiting the 
extracellular availability of one of these amino acids. Serine/glycine-depleted diets have 
already been shown to slow the growth of certain cancers (112), and we were intrigued 
by the possibility of identifying additional cancers that could benefit from this dietary 
intervention. Thus, we turned towards validating our low serine competition assay 
results as a means of determining whether our large barcoded cell line technique could 
indeed yield robust data on cellular nutrient dependencies.  
 
We attempted to validate the results of our in vitro serine depletion competition by 
conducting individual growth assays of cell lines that had been used in our barcoded 
experiment. Remarkably, we confirmed that five lymphoma cell lines that had dropped 
out of the cell competitions in low serine were in fact incredibly sensitive to serine 
restriction compared to five control cell lines. Among these cell lines sensitive to serine 
restriction were two cell lines that arrested at low serine and three cell lines that 
appeared to be complete serine auxotrophs incapable of surviving without extracellular 
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serine availability. These three serine auxotrophic cell lines had very low basal PHGDH 
expression in CCLE RNAseq data. However, the other two lymphoma cell lines that 
arrested at low serine did not have low expression of PHGDH or other genes known to 
be involved in serine synthesis. Further experiments are needed to truly rule out a 
defect in serine synthesis in these lines, such as a probing for the ability to upregulate 
serine synthesis genes in these cancer cells. If these cells do not have a defect in 
serine synthesis, it is possible that they have a substantially greater demand for serine 
than other cell lines. Another interesting observation was that 4 out of 5 of the cell lines 
we identified as sensitive to serine depletion were also previously confirmed to be 
cholesterol auxotrophs by our lab (125). Cholesterol auxotrophy in some of these cell 
lines was associated with promoter hypermethylation of a cholesterol synthesis pathway 
gene, and it is possible that serine synthesis gene promoters are similarly methylated in 
these cancer cells.  
 
Although we thought these cancers could potentially be targeted with serine/glycine-
depleted diets in vivo, we noted that these diets do not fully deplete circulating serine 
but instead bring it down to ~50 µM in serum (112). However, even at ~30 µM serine in 
vitro, these lymphoma cell lines still undergo multiple population doublings in a matter of 
days. It appears that a method of completely depleting circulating serine, down to levels 
below 3 µM based on our data, is needed to target these serine auxotrophic cancer 
cells. Such depletion could perhaps be achieved by a serine-depleting enzyme 
analogous to ASNase, which has been previously proposed (127). A method for 
depleting serine is indeed warranted, as further analysis revealed that there’s as many 
lymphoma cell lines with CCLE PHGDH levels that predict serine auxotrophy as there 
are ALL cell lines with CCLE ASNS levels that predict ASNase sensitivity.  
 
Through our work with serine depletion, we validated that our large barcoded 
competition assay can indeed pinpoint cancers that are resistant and sensitive to a 
particular nutrient depletion. Furthermore, coupling our competition assay responses 
with gene expression data proved to be very valuable in elucidating determinants of 
growth in nutrient deprivation. As ASNase is an established nutrient-depleting therapy 
already in use for ALLs, we were interested in mapping responses of other blood and 
lymphoid cancers to ASNase and also in determining pathways essential for ASNase 
resistance. We noted that many ALL cell lines in our barcoded library had been 
previously reported to be ASNase-sensitive and could serve as useful control cell lines 
in a competition grown under ASNase treatment. One challenge we encountered, 
however, was that these ALL cell lines grew too slowly in vitro to be represented even in 
control competition pools after several population doublings. However, we hypothesized 
that most cell lines in our barcoded library may undergo some change in doubling time 
when grown in vivo, which would perhaps permit ALL cells to persist through the course 
of the assay.  
 
Thus, we grew barcoded cell line pools as subcutaneous xenografts in mice that were 
divided into control and ASNase treated groups. This resulted in a comprehensive 
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mapping of the in vivo responses of 62 cell lines to ASNase. We had thought there may 
be other cancers besides ALLs that may benefit from ASNase therapy. To our surprise, 
across all of the different blood and lymphoid cancer types represented in our barcoded 
library, the ASNase-sensitive end of the response spectrum contained almost 
exclusively ALL cell lines. Thus, our data did not identify other cancer types that may 
benefit from ASNase monotherapy, but instead further emphasized that asparagine 
auxotrophy is a phenomenom that is intriguingly unique to ALLs. Importantly, this 
compendium of cell line response to ASNase allowed us to interrogate potential 
determinants of ASNase sensitivity in an effort to identify pathways that may be 
essential under ASNase treatment. Using CCLE mRNA expression data, we found that 
5 of the 6 most sensitive cell lines in our experiment were ALLs that expressed low 
basal ASNS levels. This was consistent with basal ASNS expression being a known 
major determinant of the cellular response to asparagine depletion. Although basal 
ASNS expression did appear to predict many of the growth responses in our data, it 
was not a perfect predictor, and our data suggested there may be additional 
determinants of ASNase sensitivity.  
 
In order to further elucidate determinants of ASNase response, we performed a 
negative selection genetic screen to identify genes that are required for maintaining 
ASNase resistance in the Jurkat T-ALL cell line. This cell line was appropriate for this 
screen because it was one of the few ALLs in our in vivo competition assay that was not 
sensitive to ASNase. As discussed previously, there is already evidence that increasing 
the availability of certain nutrients through diet can affect response to a different 
component of ALL therapy, the DHFR inhibitor methotrexate. Thus, we were particularly 
interested in seeing whether utilization of any particular nutrients affects response to 
ASNase in ALLs. Our metabolism-focused sgRNA library was well-suited to investigate 
this question, as it targets many transporters and enzymes involved in nutrient uptake 
and processing.  
 
Consistent with our barcoded competition assay highlighting the importance of ASNS 
expression under ASNase treatment, ASNS was the top hit of our genetic screen. 
ASNS is the final step in de novo asparagine synthesis, and as discussed in detail in 
Chapter 2, several other scoring genes appeared to delineate a particular metabolic 
route as essential for providing the aspartate substrates used by ASNS to make 
asparagine. In brief, these genes were SLC1A5, SLC25A12, FH, MDH2, and GOT2. 
The scoring of these genes suggested that glutamine is taken up by Jurkat cells, 
metabolized through the forward TCA cycle to produce oxaloacetate, and that 
oxaloacetate is then converted to aspartate. The results of our genetic screen were 
intriguing for multiple reasons.  
 
Firstly, many cancer types have been shown to utilize glutamine for filling their TCA 
cycle (a process termed glutamine anaplerosis) (115). Thus, the results of our genetic 
screen may delineate a pathway towards asparagine used by other cancer types. 
Secondly, although the aforementioned genes along this pathway all scored strongly, 
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the second top hit in our screen was actually a gene that does not directly interact with 
an asparagine precursor. This gene was TPK1, which encodes the kinase that converts 
the vitamin thiamine into its activated derivative TPP.  
 
TPP is used as a cofactor in several metabolic enzyme complexes, but our screen 
suggested that its role under ASNase treatment was likely to enable the activity of 
AKGDH in the TCA cycle. As TPP is derived from thiamine, an essential nutrient that 
must be obtained from the environment, we became interested in determining whether 
extracellular availability of thiamine may influence ASNase sensitivity of glutamine-
anaplerotic cells. We felt this would be a significant finding, as there are only a few 
reported cases in which a nutrient affects therapy. Furthermore, it would mean that 
more than one component of ALL therapy could be influenced by a nutrient obtained 
through diet. To begin to answer whether thiamine availability affects ASNase response, 
we first aimed to confirm that maintaining TPP levels through TPK1 is essential for 
growth under ASNase.  
 
Thiamine, as a vitamin, is a dietary requirement in humans, and its only established 
physiological role is to become TPP for use as a cofactor (116). TPK1 is the only 
enzyme known to convert thiamine to TPP in humans. Thus, we anticipated that TPK1 
would be an essential gene in cultured cells, and to our knowledge, full TPK1 knockouts 
in a human cell line have never been reported. Intriguingly, TPK1 did not appear to be 
essential based on the sgRNA readouts of our genetic screen. Abundance of sgRNAs 
targeting TPK1 did not change in the untreated condition of our genetic screen after 
several doublings. We hypothesized that this may be due to multiple reasons. Free TPP 
may have been present in the screening media due to release from dead or live cells. In 
later experiments, we ruled out that FBS contributed significant TPP in our screens, as 
even mixed population TPK1 KOs cannot grow in cell culture media supplemented with 
regular FBS. An additional consideration is that the half-life of TPP in cells may be on 
the order of several days (128). Regardless of its source, if free TPP was present in the 
media, then TPK1 KOs would need to have a TPP transporter to utilize this source, 
which to date appears to have only been described in colonocytes (129). Overall, the 
observation of TPK1 appearing non-lethal in our screen was puzzling, but had important 
implications for interpretation of gene essentiality screens. In large datasets of 
essentiality screens, it is possible that some metabolic genes will not appear as 
essential if the product of this gene is present in sufficient quantity in the media due to 
release from other cells or as a component of the cell culture media itself. To us, the 
most intriguing aspect of these TPK1 screen results were that a therapeutic window 
appeared to exist where cells could have enough TPP to proliferate, unless treated with 
ASNase.  
 
By supplementing TPP in cell culture media, I was able to successfully generate 
CRISPR/Cas9-mediated clonal knockouts of TPK1 using the Jurkat cell line. We found 
that loss of TPK1 is indeed lethal but that with sufficient exogenous TPP, TPK1 KO cells 
could be made to proliferate at the same level as their WT counterparts. Only 
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nanomolar amounts of TPP were necessary to rescue TPK1 KOs from death, 
suggesting the presence of a high-affinity TPP transporter in Jurkat cells. Our TPK1 
KOs could perhaps be used to identify such a transporter using a secondary genetic 
screen for genes required for these KOs to proliferate under minimal supplemental TPP. 
Furthermore, these KOs can be used by others for studying the various metabolic 
processes dependent on TPP. In our work, we focused on validating that TPP 
availability enables de novo asparagine synthesis and ASNase resistance.  
 
To perform cell proliferation assays with TPK1 KOs, I found a minimum media 
concentration of supplemental TPP that would allow for routine culture of these cells, 
which resulted in similar doubling times as parental cells. Importantly, this minimum 
concentration allows for plating growth assays in which TPK1 KOs die within 5 days, 
which is a typical length for a cell proliferation experiment. Thus, these cell culture 
practices can now be easily used by others to determine the influence of TPP 
availability on cellular processes of interest. To determine whether TPP availability 
affects ASNase response, I then established a range of TPP concentrations in which 
TPK1 KOs would go from death, to mild proliferation, to a proliferation rate that was only 
mildly growth-limiting relative to the growth of both KO clones in high-dose TPP and 
parental controls. This range was narrow and on the nanomolar level (0 to 5 nM), 
demonstrating the potent effect of TPP on the viability of cells, and further illustrating the 
presence of an unknown high-affinity TPP transporter. Furthermore, this range was near 
the human plasma range of thiamine (6.6 to 43 nM), which suggested that our 
experiments within these conditions may have physiological relevance. To validate the 
results of our ASNase genetic screen, we performed proliferation assays of TPK1 KOs 
in 0 to 5 nM TPP in the presence and absence of ASNase. Interestingly, when 
supplemental TPP was limiting for proliferation, cells became significantly sensitized to 
ASNase. Finally, we confirmed that the effects of TPP limitation on both general growth 
and ASNase response of KO clones could be rescued by overexpressing a sgRNA-
resistant TPK1 cDNA, validating the results of our genetic screen.  
 
Having established that TPP does indeed enable growth under ASNase treatment, we 
next aimed to test whether this is due to TPP being required for AKGDH activity during 
utilization of extracellular glutamine to make asparagine. As detailed in Chapter 3, we 
performed glutamine tracing studies to answer this question. The results of this were 
consistent with our genetic screen results that suggested a metabolic pathway from 
extracellular glutamine to intracellular asparagine is essential under asparagine 
depletion by ASNase. Furthermore, our data pinpointed that the role of TPP during this 
response to ASNase treatment is indeed to enable the activity of AKGDH. In some 
cancers, alpha-ketoglutarate derived from glutamine can proceed in the reverse 
direction of the TCA cycle to make citrate, in a process called reductive carboxylation 
(130). Citrate could then be exported to the cytoplasm to be used to generate 
oxaloacetate via ACLY, which could then proceed through GOT1 and ASNS to generate 
asparagine as an adaptation to asparagine depletion. However, in our experiments, 
labeling suggested that citrate is primarily derived through forward TCA in Jurkat cells. 
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Furthermore, the minimal M+3 asparagine labeling in our data suggested that Jurkat 
cells do not generate substantial asparagine through a reverse TCA route. Thus, our 
data suggests that TPP is essential for the primary metabolic pathway that these cells 
can utilize to make asparagine from glutamine. This could potentially be the case in 
other glutamine-anaplerotic cancers as well.  
 
Overall, our studies with TPK1 KOs demonstrated that TPP enables asparagine 
synthesis under extracellular asparagine depletion, and consequently, that sufficient 
TPP is needed for maximal ASNase resistance. Supplemental TPP was mildly growth-
limiting for TPK1 KOs at extracellular concentrations that were similar to the normal 
concentration of thiamine in human plasma, and ASNase sensitivity was exacerbated 
when TPP was limiting. We hypothesized that there may be some cancers for which 
physiological thiamine levels are limiting, and that these cancers may have increased 
ASNase sensitivity at these limiting concentrations relative to when in supra-
physiological thiamine concentrations like that found in conventional media. To first test 
whether physiologically-relevant thiamine levels could be growth-limiting for some 
cancers, we decided to apply our barcoded competition assay technique. Whether a 
vitamin can be growth-limiting at physiological concentrations, such that excess 
supplementation could exacerbate its growth, was an interesting concept that appeared 
to be largely understudied. Thus, we decided to study barcoded cell line responses to 
not only in vitro limitation of thiamine, but also of other vitamins.  
 
Interestingly, we found that in low thiamine, low biotin, and low niacin, subsets of cancer 
cell lines were particularly sensitive to the vitamin limitation. These cancer types may 
have defects in vitamin utilization processes such as import, causing them to require 
greater extracellular availability of a particular vitamin to obtain sufficient intracellular 
pools for maximal proliferation. Alternatively, it is possible that these cancers have a 
greater dependence on particular metabolic pathways that require a vitamin-derived 
cofactor. Overall, this dataset provided a mapping of how several cancer types respond 
to fluctuating vitamin levels, and demonstrated that some cancers can be more 
dependent on extracellular vitamin levels than others. Further study of why some 
cancers have increased dependencies on biotin and niacin is needed, but we next 
focused on investigating why certain cancers exhibited sub-optimal proliferation when 
media thiamine was lowered to physiologically-relevant concentrations.   
 
Correlating the barcoded competition assay growth responses in low thiamine with 
CCLE mRNA expression data of metabolic genes gave thiamine transporter SLC19A2 
as a top hit. To further support this data, we also performed a CRISPR/Cas9-based 
metabolism-focused genetic screen for genes essential for growth in low thiamine. 
SLC19A2 also scored in this functional screen, suggesting SLC19A2 expression does 
indeed influence growth capacity at low, physiologically-relevant thiamine levels. 
Interestingly, previous work had shown that the thiamine transporters SLC19A2 and 
SLC19A3 were expressed in lower levels in some breast and lung cancers relative to 
normal tissue counterparts (13, 131). Follow-up work showed that breast cancers with 
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low SLC19A3 may have increased dependence on extracellular thiamine, a 
dependency that can potentially be exploited by thiamine depletion with the drug 
thiaminase (14). Thiaminase was also found to have a cytotoxic effect in other cancer 
types, including leukemias, likely due to the general essentiality of thiamine for cell 
viability (16, 132). Interestingly, our analysis of the ~1,000 cell lines in CCLE suggested 
that SLC19A3 is not expressed in most cancer cell lines. This suggests that SLC19A2 is 
the primary known thiamine transporter in most cancers. Additionally, our barcoded 
competition assay and genetic screen approaches both suggested that expression of 
SLC19A2 is a major determinant of cellular growth under thiamine limitation. 
Thiaminase-induced depletion can be toxic over time (14), but our data suggested that 
physiologically-relevant thiamine concentrations could already be growth-limiting for 
some cancers with low SLC19A2. As mildly-limiting TPP availability was sufficient to 
sensitize TPK1 KOs to ASNase, we next aimed to test whether physiological thiamine 
could be limiting for both growth and ASNase response of SLC19A2-low cancer cells.  
 
We next identified multiple SLC19A2-low ALL cancer cell lines. Two of the SLC19A2-
low cell lines identified, REH and NALM6, were notable as being some of the few 
ASNase-resistant ALL cell lines in our in vivo barcoded competition. We hypothesized 
that lowering extracellular thiamine to physiological levels could be limiting for these 
SLC19A2-low cell lines, and would sensitize them to ASNase. Indeed, simply lowering 
media thiamine ~100-fold from standard RPMI concentration to a more physiological 
level led to thiamine becoming slightly growth-limiting for REH, which was associated 
with a greater ASNase response. Furthermore, expressing a SLC19A2 cDNA in REH 
was sufficient to rescue both the sub-optimal growth and increased ASNase sensitivity 
seen at lower thiamine. As detailed in Chapter 4, we went on to confirm in a panel of 
wild-type cell lines that SLC19A2 was in fact a determinant of growth and ASNase 
response at human plasma thiamine concentrations. Additionally, SLC19A2 was 
necessary for SLC19A2-high cells to maintain maximal growth and ASNase resistance 
at physiological thiamine. Of translational importance, we also found that low expression 
of SLC19A2 was not a phenomenon solely observed in cultured cells. By analyzing 
human ALL tumor mRNA expression data, we first confirmed that SLC19A3 is largely 
not expressed in these human tumors, suggesting that SLC19A2 is the primary thiamine 
transporter in these ALLs. Finally, we confirmed that patient tumors exhibit a range of 
SLC19A2 expression and that SLC19A2-low tumors do in fact exist, consistent with 
CCLE cell line data.  
 
We next aimed to test whether extracellular thiamine affects ASNase response of 
SLC19A2-low cells in vivo. To do this, we first had to determine how to modulate 
circulating plasma thiamine in mice through diet. This posed a challenge, as it is well 
known that dietary thiamine deficiency is toxic in humans, and thiaminase administration 
in mice had been shown to have some toxicity over time. However, our cell culture 
experiments suggested that we did not have to cause a thiamine deficient state to 
sensitize cancers to ASNase. Instead, our in vitro data suggested that SLC19A2-low 
cells intriguingly already have an inherent ASNase sensitivity at physiological thiamine 
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levels, which can be inadvertently rescued through excess thiamine supplementation. 
Thus, we aimed to determine whether physiological human thiamine plasma 
concentrations are already sufficient to sensitize SLC19A2-low leukemia cells to 
ASNase in an in vivo model. We had observed that SLC19A2-low REH cells were 
ASNase-resistant when engrafted in mice fed standard chow and when grown in media 
containing supra-physiological thiamine, but that humanizing thiamine levels in vitro 
sensitized these cells to ASNase. Thus, we hypothesized that standard mouse chow 
contained supra-physiological thiamine levels and that SLC19A2-low cells would be 
more sensitive to ASNase if circulating thiamine was humanized. Plasma profiling 
revealed that standard mouse chow did indeed cause plasma of mice to have orders of 
magnitude more thiamine than human serum. This suggested that many research 
facilities may be using standard mouse diets that inadvertently over-supplement 
thiamine. As thiamine-derived TPP is involved in many metabolic processes, further 
work is perhaps warranted to determine the effects of such practices on organismal and 
cellular metabolism.  
 
To determine whether I could humanize plasma thiamine levels of mice, I conducted 
several experiments using purified ingredients diet pellets that were custom-made to be 
thiamine-free. While mice groups were fed this diet, I supplied various amounts of 
thiamine in their water bottles to determine whether I could achieve human plasma 
thiamine levels without adverse effects. I found that it was indeed possible to achieve a 
human thiamine plasma level of ~10 nM in mice without causing any weight loss or 
other observable adverse reactions. The diet used to achieve these plasma levels 
consisted of thiamine-free purified pellets combined with a low thiamine amount within 
mouse water bottles, and the amount provided in water could be raised to obtain an 
appropriate high-thiamine control diet. In the end, I had a Low Thiamine diet that 
resulted in a circulating thiamine content comparable to that of human serum, and a 
High Thiamine diet that differed only in water thiamine content. Furthermore, this High 
Thiamine diet was designed to mimic plasma thiamine levels obtained with standard 
mouse chow. To our knowledge, no other mouse diets currently exist for providing 
circulating thiamine at the level of human plasma. This physiological low thiamine diet, 
and its high thiamine diet control, may be of value to others studying the effects of 
thiamine availability on biological processes in vivo.  
 
After developing these diets that allowed us to modulate plasma thiamine levels, our 
Low Thiamine and High Thiamine diets were fed to NSG mice. We subsequently 
administered SLC19A2-low REH cells by tail-vein to these mice to form orthotopic ALL 
xenografts. Compared to the High Thiamine group that had circulating plasma thiamine 
levels comparable to that obtained with standard chow, neither lowering dietary 
thiamine or treatment with ASNase caused a significant effect on survival from 
leukemia. Remarkably, combining a lower dietary thiamine intake with ASNase 
treatment did significantly extend survival. Together with our in vitro experiments, our 
results demonstrate that lowering thiamine to human physiological levels in culture 
media, and in mouse plasma through diet, increases the response of a subset of cancer 
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cell lines to ASNase, an important chemotherapeutic in the treatment of ALL (Figure 
6.1). This subset is defined by low expression of SLC19A2, the primary thiamine 
transporter in ALL tumor samples.  
 
 
Figure 6.1. Environmental thiamine influences ASNase sensitivity in a subset of 
leukemia cells with low SLC19A2 expression. 
 
 
This work raises the possibility that low SLC19A2 expression may be associated with 
greater patient response to ASNase. Importantly, however, increasing blood thiamine 
concentrations through excess supplementation could diminish ASNase efficacy in such 
cancers. More broadly, this thesis provides a proof of principle that humanizing the 
vitamin levels of both in vitro and in vivo models can affect therapeutic sensitivity of 




CHAPTER 7. Future directions and perspectives 
 
 
7.1 Relevance to vitamin supplementation during cancer treatment 
 
Our results suggest that extracellular thiamine availability influences ASNase response 
of a subset of leukemia cells. Indeed, when combined with a change in dietary thiamine 
intake, ASNase treatment extends survival in a mouse leukemia model. It is important to 
note that the low thiamine dietary intervention used here was equivalent to simply 
maintaining normal human serum levels, and was sufficient to sensitize SLC19A2-low 
leukemia cells to ASNase. Lowering thiamine levels further than the normal 
physiological range for therapeutic purposes in experimental or clinical settings would 
likely have adverse consequences, due to the diverse functions of TPP in normal cell 
types. In addition to its role in the AKGDH complex, TPP serves as a cofactor for 
various other enzymes, including the pyruvate dehydrogenase (PDH) complex, the 
branched-chain alpha-ketoacid dehydrogenase complex, and transketolase (133). Thus, 
biochemical abnormalities, such as lactic acidosis resulting from diminished PDH 
activity, are among the symptoms observed in patients with nutritional thiamine 
deficiency (133-135).  
 
 Although high thiamine supplementation is warranted in cases of deficiency, 
prophylactic use has been suggested with limited evidence for other scenarios, 
including preventing potential side effects of adult ASNase administration (136, 137). 
Such use in ALL patients should therefore be weighed with the possibility that excess 
blood thiamine may negatively impact ASNase response of a subset of cancers. 
However, human studies are needed to further elucidate the effect of excess thiamine 
on therapeutic response. To determine whether SLC19A2 expression is predictive of 
responses to ASNase-containing regimens and patient survival, it would be necessary 
to measure patient plasma thiamine levels during treatment since having supra-
physiological levels could affect response. Another possibility is to document vitamin 
supplementation during clinical trials, which has been done for those with antioxidant 
properties like vitamin E, and their use is now discouraged while undergoing 
chemotherapy and radiotherapy for various cancers (138-140).  Collectively, our work 
adds to the growing list of studies available that probe whether excess vitamin 
supplementation may be detrimental during chemotherapy (141). Unfortunately, the lack 
of clinical reports on this topic has translated to non-uniform physician advice with 
regards to taking vitamin regimens during cancer treatment (142, 143). 
 
7.2 Implications for vitamin use in pre-clinical in vitro and in vivo studies 
 
Our work emphasizes the need to better recapitulate tumor nutrient environment in vitro. 
Conventional cell culture media are complex, containing both proteinogenic and non-
proteinogenic amino acids, important polar metabolites such as glucose and 
glutathione, inorganic salts such as NaCl, trace elements, and of course, essential 
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vitamins. Recently, custom media have been designed to contain physiologically-
relevant concentrations of these components. However, it is important to note some of 
the limitations of these physiological media, and what can be done to better simulate 
nutrient environments in the future.  
 
Physiological environments, such as that of blood plasma, contain many more 
metabolites than that found in synthetic culture media. Thus, quite reasonably, recent 
reports of plasma-like media focused on manipulating only a portion of the metabolome 
found in human plasma. This is partly due to the fact that nutrients in cell culture 
systems are provided not only through the synthetic media itself, but also through the 
supplementation of media with various percentages of fetal bovine serum (FBS). FBS 
provides compounds essential for cell proliferation that are not present in chemically 
defined media, such as lipids and additional micronutrients. FBS can also be treated to 
yield variations with distinct metabolite profiles such as lipid-depleted FBS obtained by 
charcoal-stripping, or small-molecule-depleted FBS resulting from extensive dialysis (as 
used in this work). To date, cell culture media designed to mimic human plasma have 
been supplemented with either a low percentage (2.5%) of regular FBS, or a 
conventional percentage (10%) of dialyzed FBS (9, 144). These FBS practices 
contribute low amounts of the small molecule metabolites that are already present at 
defined, desired concentrations in the synthetic media. Thus, the final complete media 
that results does indeed contain human plasma-like levels of the metabolites considered 
in the synthetic media design. However, it remains unclear how the final media 
concentrations of other metabolites, such as lipids, compare to that of human plasma. 
Additionally, these recent plasma-like media studies did not attempt to mimic the vitamin 
concentrations of human plasma, and vitamin levels in these media remain at the supra-
physiological concentrations found in conventional media. To contrast, the work 
described here only manipulated cell culture media so that it contained human plasma 
levels of thiamine, and the levels of other vitamins and metabolites in our experiments 
remained at conventional cell culture concentrations. However, manipulating the levels 
of thiamine alone caused significant changes in leukemia cell responses to an important 
therapeutic, demonstrating a need for considering vitamins during physiological media 
design. Future development of plasma-like media should improve upon the important 
recent variations, by attempting to humanize the levels of additional metabolites such as 
lipids and vitamins. Such media formulations may prove valuable for studying the 
biology and therapeutic responses of blood cancers in vitro.    
 
Different tissues may provide metabolically distinct environments in the body, and 
plasma-like media may not be suitable for the study of all cell types and cancers. Thus, 
it may be useful to consider designing custom media on a case-by-case basis, so as to 
best recapitulate the relevant tissue environment. This concept was exemplified by a 
recent study that developed a cell culture medium that mimics the metabolic 
environment of the brain, which can be used for studying neuronal biology in vitro (145). 
However, it is important to note that the metabolic environments of tumors can differ 
from that of blood and normal tissues (146). Thus, if it is possible to characterize a 
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tumor environment of interest, then it may be useful to do in vitro studies of this cancer 
type in a medium that metabolically mimics the native tumor environment.  
 
In vivo nutrient environments, particularly those experienced by cancer cells in 
orthotopic xenografts and autochthonous tumors, may be thought of as more 
physiologically-relevant than that of cell culture systems. Importantly, there has been an 
abundance of recent evidence demonstrating that manipulation of these nutrient 
environments through diet can influence tumor growth (1, 5). In our work, we have 
demonstrated that conventional mouse chow can lead to supra-physiological levels of a 
vitamin in mouse plasma. Thus, it is possible that other in vivo cancer studies are 
currently utilizing animal diets that cause non-physiological levels of metabolites to 
circulate in blood, and as a result, through tumor microenvironments. Furthermore, we 
showed that bringing the plasma level of thiamine down to normal human levels in mice 
affected response of orthotopic leukemia xenografts to an established therapeutic. It 
remains to be determined whether humanizing the plasma levels of other nutrients in 
mouse cancer models could affect tumor growth or response to anti-cancer therapy, but 
our results suggest such studies are warranted.   
 
7.3 Further characterization of cancer nutrient dependencies is warranted 
 
Recently, compounds have been designed for plasma depletion of amino acids other 
than asparagine. These include an arginase, a cyst(e)inase, and a methioninase (147-
149). However, these compounds have only been tested on a subset of cancer models. 
Custom diets have also been used to deplete certain amino acids in vivo, such as 
serine and glycine (112). These dietary depletions have slowed tumor growth in some 
cancer models, but also remain unstudied in many cancers. The techniques used in this 
thesis, particularly barcode-based cell competition assays, can be used for a systematic 
mapping of the responses of several cancers to various nutrient depletions. Although 
we conducted some amino acid and vitamin deprivation studies in our work, it would be 
interesting to see how barcoded libraries consisting of other cancer types may fare 
under the conditions studied here or in other nutrient depletions. This would, at the very 
least, pinpoint cancers that could be therapeutically targeted with recently described 
compounds and dietary interventions. 
 
Identifying cancers that are resistant and sensitive to particular nutrient depletions can 
also lead us towards pinpointing biological pathways that are essential for maintaining 
intracellular nutrient levels in specific cancer subtypes. This can lead to additional 
translational findings, such as alternative ways to target cancers with a particular 
nutrient dependency besides simply limiting dietary intake of the nutrient or depleting it 
from plasma with an enzyme. For instance, mapping cell line responses to cholesterol 
limitation identified a subset of cancers that cannot synthesize cholesterol and depend 
on its uptake from the environment for proliferation (125). Thus, the LDLR gene required 
for cholesterol uptake was found to be a potential therapeutic target in this subset of 
cancers.  
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In this work, we investigated the responses of several barcoded cancer cell lines, 
primarily of blood and lymphoid origin, to depletion of non-essential amino acids and 
vitamins. However, further work is needed to validate whether some of the cancer 
subsets in our assays may be targetable with a nutrient-depleting drug or dietary 
intervention. It will also be interesting to investigate the genetic determinants of growth 
under the nutrient limitations that we have not yet followed up. In particular, future work 
on vitamin depletions is warranted, as vitamins are relatively understudied in the cancer 
metabolism field. Further work could determine whether subsets of cancers that 
proliferate less under particular vitamin limitations may have targetable vitamin 
utilization deficiencies, as exemplified by SLC19A2-low cells being targetable with 





CHAPTER 8. Materials and Methods 
 
 
8.1 Experimental design 
 
This study was designed to investigate the metabolic determinants of leukemia cell 
response to ASNase treatment. To address this objective, we (i) performed unbiased 
genetic screens to find genes that are essential for proliferation under ASNase 
treatment, (ii) used loss-of-function studies and metabolite profiling to validate that 
TPK1 enables ASNase resistance by producing the cofactor TPP, which allows 
asparagine synthesis in glutamine-anaplerotic leukemia cells, (iii) used a DNA-barcoded 
cell line competition assay, a genetic screen, and gain- and loss-of-function studies to 
identify that physiological thiamine is limiting for ASNase response of a subset of 
leukemia cell lines with low expression of the thiamine transporter SLC19A2, and (iv) 
orthotopically engrafted leukemia cells with endogenously-low SLC19A2 in NSG mice to 
show that dietary thiamine can influence ASNase sensitivity in leukemia.  
 
8.2 Compounds, Cell lines, Cell Culture, and Constructs  
 
Antibodies to GAPDH (GTX627408) were from GeneTex, and to TPK1 from Proteintech 
(10942-1-AP). Conjugated Donkey Anti-Mouse IR-Dye 680LT and Donkey Anti-Rabbit 
IR-Dye 800CW were from LI-COR Biosciences. 
 
Asparagine, TPP, polybrene, and puromycin were from Sigma; blasticidin from 
Invivogen; D-glucose from VWR; L-glutamine from Gibco; thiamine hydrochloride from 
MP Biomedicals; E. coli L-asparaginase from BioVendor.  
 
For glutamine tracing, a powder base media of RPMI without amino acids (R9010-01, 
US Biological) was supplemented with all individual amino acids (except for asparagine 
and glutamine) and glucose at RPMI concentrations. [U-13C]-glutamine (CLM-1822-H, 
Cambridge Isotope Laboratories(CIL)) was used for tracing, and asparagine was 
present or absent at RPMI concentration as detailed in experiment discussion. For 
thiamine uptake experiments, Thiamine-(4-methyl-13C-thiazol-5-yl-13C3) hydrochloride 
(“13C-thiamine”, 731188, Sigma) was added to cells in Hank’s Balanced Salt Solution 
containing calcium chloride and magnesium chloride (“HBSS”, 24020-117, Gibco). In 
tracing, uptake, and plasma profiling experiments, extraction solvents contained 15N and 
13C fully-labeled internal amino acid standards (MSK-A2-1.2, CIL) for normalization. 
 
All human cell lines used were originally purchased from ATCC or DSMZ, or obtained 
from the Sabatini and Weinberg labs (Whitehead Institute). Cell lines were verified to be 
free of mycoplasma, and authenticated by STR profiling. Cell lines were typically 
maintained in “standard RPMI”: RPMI-1640 medium containing 2 mM glutamine 
(Gibco), 10% fetal bovine serum (“FBS”, Sigma), and penicillin-streptomycin (Gibco), at 
 55 
37 C and 5% CO2, unless otherwise noted. For all experiments, cells were counted with 
a Beckman Z2 Coulter Counter.  
 
The DNA-barcoded cell line competition assay and CRISPR-based screen done in low 
thiamine media used thiamine-free RPMIs supplemented with 10% dialyzed FBS 
(“dialyzed FBS”, 26400044, Gibco). All thiamine-free RPMIs were made with 
glucose and glutamine at standard RPMI concentrations (11 and 2 mM, 
respectively). For the competition assay, a powder base media of RPMI without 
vitamins (US Biological) was supplemented with all individual vitamins (except for 
thiamine) at RPMI concentrations. The CRISPR screen used a different powder base 
media of RPMI made without thiamine (R9011-01, US Biological), which was used for 
all other experiments that utilized thiamine-free RPMI. 
 
For manipulating thiamine levels in the REH EV and SLC19A2 OE experiments, 
thiamine-free RPMI was combined with 10% non-dialyzed FBS. For achieving 
nanomolar thiamine levels that approximated physiological thiamine, thiamine-
free RPMI was combined with 10% “double-dialyzed FBS”, obtained by further in-
house dialysis of Gibco’s dialyzed FBS. In-house dialysis was performed at 4 C 
against a 20X volume of PBS, using regenerated cellulose dialysis tubing (21-
152-9, Fisherbrand), with a PBS change done after at least 8 hours of stirring, 
such that 4 total PBS volumes were spent.  
 
Lentiviral sgTPK1 vector was generated via ligation of hybridized oligos (below) into 
lentiCRISPR-v2-puro, and lentiviral sgSLC19A2 vector was generated similarly (oligos 
below) but using lentiCRISPR-v1-RFP. Both of these vectors were linearized with 
BsmBI (New England BioLabs), and non-linearized vectors were used for Vector 
Controls. sgRNA-resistant TPK1, or SLC19A2, cDNA gene blocks were cloned into 
pMXs-IRES-blast by Gibson assembly, and uncut vector used as Vector Control. 
 





Guide 3 in CRISPR/Cas9 screen, referred to as sgSLC19A2_1 in proliferation assays: 
sgSLC19A2_3F, 5’-caccGAGGCTGGCGAAGAAGCCGT-3’;  
sgSLC19A2_3R, 5’-aaacACGGCTTCTTCGCCAGCCTC-3’. 
 
Guide 4 in CRISPR/Cas9 screen, referred to as sgSLC19A2_2 in proliferation assays: 





8.3 Generation of Knockout and cDNA Overexpression Cell Lines  
 
Lentiviral sgTPK1 and sgSLC19A2 vectors generated as described above were 
transfected into HEK293T cells with lentiviral packaging vectors VSV-G and Delta-VPR. 
For the overexpression of TPK1 or SLC19A2, retroviral vector with cDNA generated as 
above was transfected into HEK293T cells with retroviral packaging vectors Gag-pol 
and VSV-G. X-tremeGENE reagent (Roche) was used for transfection. After 24 h, cells 
were given fresh media. 48 hours after transfection, virus-containing media 
supernatants were filtered through a 0.45 µm filter to eliminate cells. Cells to be 
transduced were plated in 6-well tissue culture plates with appropriate virus and 8 
mg/ml of polybrene. Cells were then spin-infected by plate centrifugation at 1,100 g for 
1.5 h at 32 C. After 24 h, cells were given fresh media. At least 48 h after infection, 
transduced cells were selected with puromycin, blasticidin, or by bulk-sorting on a BD 
FACSAria (same gating for all samples, resulting in top 3-6% of RFP+ cells). Clonal 
TPK1-knockout cells were generated from a single cell isolated by serial dilution of 
transduced cells into a 96-well plate, in 0.2 mL of 100 µM TPP-supplemented standard 
RPMI. Single cell clones were grown for ~3 weeks, and the resultant clones were 
evaluated for TPK1 knockout by immunoblotting. TPK1 KOs were then maintained in 
standard RPMI containing 20 nM TPP, as were the relevant Vector Control and cDNA-
add-back controls, for at least 1 week prior to proliferation assays. Mixed population 
cells transduced with sgSLC19A2s or Vector Control were maintained in standard 
RPMI, as this already over-supplements thiamine at 3 µM. Of note, REH and Jurkat 
cells expressing a luciferase reporter construct were used for generating the Vector- or 
SLC19A2-overexpression pair, and the Vector-, sgSLC19A2_1-, or sgSLC19A2_2-
expressing lines, respectively. 
 
8.4 Immunoblotting  
 
Cells were first collected by centrifugation at 300 g for 4 min, and washed twice with 
PBS. For blotting TPK1, cells were then lysed in cold RIPA buffer (20 mM Tris-Cl pH 
7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.5% sodium 
deoxycholate) supplemented with protease inhibitors (Roche), for 5 min on ice. 
Supernatants were then collected by centrifugation at 20,000 g for 8 min at 4 C, and 
protein concentration was determined using the Pierce BCA Protein Assay Kit (Thermo 
Scientific) with a bovine serum albumin protein standard series. Samples were resolved 
on 12% SDS-PAGE gels and analyzed by immunoblotting using antibodies listed above, 
and a LI-COR Odyssey CLx Imaging System coupled with Image Studio Lite. 
 
8.5 RNA Extraction, Reverse Transcription, and Real-time Quantitative PCR 
 
RNA was extracted using the QIAGEN RNeasy mini kit, and 1 µg of RNA was reverse 
transcribed using the Superscript III Reverse Transcriptase kit (Invitrogen), both 
according to the manufacturer’s instructions. Real-time quantitative PCR (qPCR) was 
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performed using SYBR Green PCR Master Mix (Applied Biosystems) and GAPDH was 
used as a housekeeping control. qPCR primer sequences were as follows:  
GAPDH forward, 5’-TTGGTATCGTGGAAGGACTC-3’ 
GAPDH reverse, 5’-ACAGTCTTCTGGGTGGCAGT-3’ 
SLC19A2 forward, 5’-GGCCGGACAAGAACCTGAC-3’ 
SLC19A2 reverse, 5’-ACACAGGAAACAGTAGCACCA-3’ 
 
8.6 Proliferation Assays  
 
Cells were plated in 96-well plates at 1,000 cells per well in triplicate in a final volume of 
0.2 ml in indicated medias and treatments. After 5-9 days of growth (depending on 
proliferation rate), 40 µl of CellTiter-Glo reagent (Promega) was added and 
luminescence was read on a SpectraMax M3 plate reader (Molecular Devices). For 
each experiment, cells were also plated in triplicate in untreated media for an initial 
luminescence time point for normalization. For each well, fold change in luminescence 
was calculated and reported on a log2 scale. In all proliferation assays, we used an 
ASNase dose ≤ 0.001 U/mL, which is a dose previously shown to deplete asparagine in 
medium within 24 h, without affecting glutamine levels (150). In assays that required 
achieving low thiamine levels, cells were first pre-incubated for 5-9 days in the same low 
thiamine base media that was subsequently used for plating proliferation assays. 
Proliferation assays were plated multiple times within this pre-incubation period with 
similarly reproduced results.  
 
8.7 Mouse studies 
 
Animal studies were conducted according to a protocol approved by the Institutional 
Animal Care and Use Committee (IACUC) at the Rockefeller University. All experiments 
used age- and gender-matched NSG mice that were maintained on a standard light-
dark cycle, with food and water provided ad libitum. Subcutaneous xenograft tumors for 
DNA-barcoded competition assays were initiated by injecting 1.5 million of the pooled 
cells in 100 µl of DMEM (Gibco) with 30% Matrigel (Corning), once on each mouse 
flank. These mice were fed 5B1Q (TestDiet), a chow-based diet. Leukemia xenografts 
were initiated by injecting 750,000 REH cells in 100 µl PBS through the tail vein. 2 
weeks prior to tail-vein injections, these mice were switched from 5B1Q to a purified diet 
of thiamine-deficient AIN-93G pellets (Dyets, Inc.) coupled with high or low thiamine 
supplementation in water as described below. 1 week prior to tail-veins, REH cells were 
switched from standard RPMI to a low thiamine media (thiamine-free RPMI + dialyzed 
FBS) to remove excess thiamine from cells. To determine survival after leukemia 
engraftment, weights were first checked weekly. After the first signs of progressive 
disease, mice were monitored daily for deaths or signs of endpoint, and weights taken 
at a minimum of twice weekly. Humane endpoints were 1) 20% weight loss from initial 
weight, and 2) other obvious signs of disease such as hind limb dysfunction or 
significant distress.   
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Low Thiamine groups were maintained by combining thiamine-deficient AIN-93G pellets 
with water bottles containing 5 µM thiamine. High Thiamine groups were maintained by 
combining the same thiamine-deficient pellets with 125 µM thiamine in water. Mice were 
treated with L-asparaginase (1000 U/kg) daily for cell competition assays (2 weeks), 
and twice weekly for leukemia xenograft experiments (~4 weeks). For all plasma 
profiling, whole blood was collected using EDTA-coated capillaries or tubes by tail clip 
(except for the 39d Low Thiamine time-point and the Chow vs High Thiamine data of 
Figure 5.2, for which submandibular bleeds were done), then centrifuged at 20,000 g for 
5 min at 4 C to yield the plasma supernatants used for LC-MS analysis. 
 
8.8 Metabolite Profiling: Isotope Tracing, Isotope Uptake, Plasma Profiling  
 
For glutamine tracing, the 3 cell types were first taken from their maintenance media (20 
nM TPP), and washed twice with PBS. Cells were then plated at 500,000 cells/ml in 
media containing 2.5 nM TPP, for ~1 day, to begin TPP depletion. To begin the 
experiment, cells were washed again then plated in triplicate per condition in 6-well 
plates at 1 million cells/ml, in a custom RPMI (described above) containing no 
asparagine, no TPP, and 2 mM [U-13C]-glutamine (supplemented with 10% dialyzed 
FBS). TPP (at RPMI thiamine concentration) and asparagine (at RPMI concentration) 
were then added to wells as appropriate. After 24 h, 1 million cells from each well were 
washed twice with 1 ml of cold 0.9% NaCl; a separate tube of 1 M cells was also 
processed for each experimental condition to check protein content. After washing, 
polar metabolites were extracted in 1 ml of cold 80% methanol containing internal amino 
acid standards, by vortexing for 10 min at 4 C. Samples were then centrifuged at 20,000 
g for 15 min at 4 C, and 900 µl of supernatants stored overnight at -80 C, then nitrogen-
dried. Dried extracts were kept at -80 C until liquid chromatography / mass spectrometry 
(“LC/MS”) analysis. Dried samples were resuspended in 100 µl 50:50 acetonitrile:water 
and 2 µl was injected onto the LC/MS column. For protein quantification, NaCl-washed 
cell pellets were instead stored at -20 C until RIPA lysis and protein quantification (as 
described above for TPK1 immunoblotting).  
 
For thiamine uptake experiments, the 3 cell types were first taken from their 
maintenance in standard RPMI and washed twice with PBS. 4 million cells were then 
plated in triplicate per condition in 6-well plates at 1 million cells/ml in warm HBSS. 13C-
thiamine was then added to wells at a final concentration of 25 nM, for 5 min 
incubations at 37 C. The assay was stopped by pipetting each well into an ice-cold tube 
of HBSS containing unlabeled thiamine that came to 3 µM in the final mixture. Cells 
were then washed twice with cold 0.9% NaCl and processed as described above for 
polar metabolite extraction and LC/MS analysis. Dried samples were resuspended in 60 
µl 50:50 acetonitrile:water, and 5 µl was injected onto the LC/MS column.  
 
For plasma profiling, polar metabolites were extracted by combining plasma with cold 
75:25 acetonitrile:methanol containing internal amino acid standards. 5 µl plasma was 
combined with either 45 µl solvent for the in vivo competition assay data, or with 20 µl 
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solvent for custom thiamine diet experiments (for quantifying low abundance thiamine in 
plasma). This was followed by vortexing for 5 min at 4 C, then centrifuging at 20,000 g 
for 10 min at 4 C. Supernatants were taken immediately for LC/MS analysis, or first 
stored at -80 C for no longer than 24 h (samples were never dried). 2 µl (for competition 
assay) or 5 µl (for custom thiamine diet experiments) were injected directly onto the 
LC/MS column.  
 
LC/MS analysis was conducted on a Q Exactive benchtop orbitrap mass spectrometer 
equipped with an Ion Max source and a HESI II probe, which was coupled to a 
Vanquish UPLC system (Thermo Fisher Scientific). External mass calibration was 
performed using the standard calibration mixture every 4-6 days. Samples were injected 
onto a ZIC-pHILIC 150 × 2.1 mm (5 µm particle size) column (EMD Millipore). 
Chromatographic separation was achieved using the following conditions: buffer A was 
20 mM ammonium carbonate, 0.1% ammonium hydroxide; buffer B was acetonitrile. 
The pH for buffer was adjusted to 9.3 using formic acid. The column oven and 
autosampler tray were held at 25 C and 4 C, respectively. The chromatographic 
gradient was run at a flow rate of 0.150 ml min−1 as follows: 0–22 min: gradient from 
90% to 40% B; 22-24 min: held at 40% B; 24–24.1 min: return to 90% B; 24.1–30 min: 
hold at 90% B. The mass spectrometer was operated in full-scan, polarity switching 
mode with the spray voltage set to 3.0 kV, the heated capillary held at 275 C, and the 
HESI probe held at 250 C. The sheath gas flow was set to 40 units, the auxiliary gas 
flow was set to 15 units. The MS data acquisition was performed in a range of 55–825 
m/z, with the resolution set at 70,000, the AGC target at 10 × 106, and the maximum 
injection time at 80 msec. Relative quantitation of polar metabolites was performed with 
Skyline Daily from MacCoss Lab Software (151), using a 2 ppm mass tolerance. For all 
experiments, total signal for a metabolite was first quantified in Skyline, in which 
metabolite identification was based on mass, retention time, and the signal observed for 
an in-house chemical standard of the metabolite. The chemical standard was present in 
a separate injection of the same LC/MS run. For glutamine tracing data, natural 
abundance corrections were not performed in Skyline, as the primary mass 
isotopologues of interest were M+4 and M+5 species, which were deemed to have 
negligible natural abundance for the metabolites analyzed. For instance, naturally-
occurring asparagine is ~0.001% M+4 asparagine and naturally-occurring glutamate is 
~0.0001% M+5 glutamate. For normalization, raw signal of each metabolite was first 
normalized to the appropriate labeled internal AA standard in that injection (except for 
the thiamine uptake data, where raw signal is presented because no signal was 
detected in sgSLC19A2 samples). Metabolite levels were also normalized by cell 
counting (per well) and BCA protein quantification (per condition) for glutamine tracing, 
by cell counting for thiamine uptake, and by plasma/serum volume as appropriate.  
 
8.9 CRISPR/Cas9-based genetic screens 
 
The metabolism-focused sgRNA library preparation, and details on performing screens, 
were previously described (152-154). sgRNA oligonucleotides were synthesized by 
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Agilent and amplified by PCR. After Illumina deep sequencing of initial and final screen 
pools, a guide score for each screen flask was defined as the log2 fold change of 
sgRNA abundance from initial to final. Gene scores for each flask were defined as the 
median of the guide scores corresponding to a gene, and the complete lists of gene 
scores were used to make the gene score vs. gene score linearity plots presented. For 
each sgRNA of a gene, the guide score for the control flask was subtracted from the 
guide score for the experimental flask, and the median of the resulting values was 
defined as the differential gene score. A gene lethality cut-off was used for differential 
gene score analysis: genes that had a gene score less than or equal to -1 in the 
appropriate control condition were removed from the gene score list, and the updated 
gene list was ranked by differential gene score of experimental vs. control to give the 
differential gene score graphs presented. Full screen results are available as 
supplementary data. 
 
8.10 DNA-barcoded cell line competition assays 
 
DNA-barcoded cell lines were generated, and competition assays performed, as 
previously described (3, 125). In brief, three unique 7-bp sequences were transduced 
into each cancer cell line using lentiviruses generated with pLKO.1-puro vector, such 
that each cell line had 3 data-points used for statistical analysis. To perform cell 
competition assays, barcoded cell lines were mixed in approximately equal amounts, an 
initial pool sample was taken, and the remainder of the pool was grown for ~2 weeks 
under indicated in vitro or in vivo conditions. At endpoint, genomic DNA was extracted 
from the initial and final pool samples, DNA barcode regions were amplified by PCR, 
and PCR amplicons were processed for Illumina deep sequencing. Fold-change of 
barcode abundance from initial to final pools was determined, and results presented as 
detailed in appropriate figures.  
 
8.11 Patient tumor and cell line RNA sequencing 
 
Patient RNAseq data for SLC19A2, SLC19A3, TPK1, and ASNS were generated by the 
Therapeutically Applicable Research to Generate Effective Treatments 
(https://ocg.cancer.gov/programs/target) initiative, phs000218. These data were part of 
the Acute Lymphoblastic Leukemia (ALL) Expansion Phase 2 TARGET Sub-study, 
phs000464, and were downloaded from the TARGET Data Matrix 
(https://ocg.cancer.gov/programs/target/data-matrix) on December 10, 2019. All files 
used were in the BCCA subdirectory and tumor sample details are indicated within the 
relevant figures. Cancer cell line RNAseq data presented throughout this study were 
obtained from the CCLE (https://portals.broadinstitute.org/ccle/data), accessed on 





8.12 Statistical Analysis 
 
Significance P values, sample sizes, and means are indicated in text or figures. Error 
bars represent standard deviation from biological replicates or independent samples as 
indicated. Statistical analyses were performed with GraphPad Prism or Microsoft Excel 
as appropriate. P ≤ 0.05 was considered statistically significant, and the specific 
statistical test used and any adjustments for multiple comparisons are indicated in the 
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